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ABSTRACT

Expression, Purification, and Characterization of the Mast Cell Proteases Chymase and
Cathepsin G
by
Brent Lockhart

Human mast cells have been associated with wound healing, allergies, inflammation,
and defense against pathogens and have been detected in tissues close to blood
vessels especially in the areas between the inside of the body and the external
environment, such as the skin, lungs, digestive tract, mouth, and nose. Previous studies
have shown that mast cells contain large granules filled with histamine, heparin,
cytokines, eicosanoids, and the serine proteases, tryptase, Chymase, and cathepsin G
(CatG). These proteases are stored and released from mast-cell granules upon
activation by antigen binding to IgE immunoglobulins on the cell surface or by direct
injury. In this study, chymase and CatG were expressed as active enzymes in the yeast
Pichia pastoris by homologous recombination of the cDNA coding for the mature active
proteases into the Pichia genome. Methanol induction resulted in the secretion of active
enzyme into the Pichia growth media and increasing levels of enzyme were detected in
the media for 5 days. Cells that secreted the highest levels of activity were selected by
kinetic assay. Active chymase was purified from the culture media with a 22% yield of
activity by a simple two-step procedure that involved hydrophobic-interaction
chromatography followed by affinity chromatography on immobilized heparin. The major
peak from the heparin column contained a single band of 30.6 kDa on SDS/PAGE. The
purified recombinant human chymase was 96% active and the yield was 2.2 mg/l of
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growth media. Active CatG was partially purified from culture media using an
ultrafiltration. Mass Spectroscopy (Maldi-Tof) data confirmed that the major protein
band was CatG, resulting in the first active human CatG to be produced recombinantly.
Additionally, the partially purified enzyme was active against both chymotrypsin and
trypsin substrates, and its reaction with inhibitors was consistent with CatG. Although
the protein yields were low, these results confirm that CatG was recombinantly
expressed.
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CHAPTER 1
INTRODUCTION
HSP In Mast and Other Cells
The human hemapoietic serine proteases (HSPs) have been found in neutrophils, Tlymphocytes, basophils, natural killer cells (NK) and mast cells (Garwicz et al. 1998;
Gullberg et al. 1999; MacIvor et al. 1999). Human mast cells have proven to play an
important role in wound healing, allergy, and defense against pathogens. These cells
have been found in tissues close to blood vessels primarily in the areas between the
inside of the body and the external environment. Examples of these areas would be the
skin, lungs, digestive tract, mouth, nose or in the skin. Mast cells have been found to
contain large granules filled with histamine, heparin, cytokines, eicosanoids and serine
proteases that are released upon antigen binding to IgE immunoglobins attached to the
cell membrane or by direct injury (Table 1). In addition, mast cells have been implicated
in rheumatoid arthritis and asthma (Faber et al. 1993; Guay et al. 2006). The HSPs in

Cell Type

Proteases

Neutrophils

Mast Cells

Cathepsin G

Cathepsin G

Elastase

Chymase

Proteinase 3

Tryptase

Azurocidin
Table 1 Cell Types and Protease They
Produce. Gullberg et al, 1997, Biosynthesis,
processing and sorting of neutrophil proteins.

neutrophils have been shown to consist of a combination of the cationic proteases
cathepsin G, elastase, protease 3, and azurocidin that although similar in sequence was
thought to
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be non-functional (Garwicz et al. 1998; Gullberg et al. 1999). Neutrophil HSPs have
been proven to be stored in the cytoplasmic azurophil granules that contain other
proteins such as defensins and myeloperoxidase or they are transported out of the cell
by “constitutive secretion” where they can attach to the cell surface. Neutrophil
proteases have also been found to be normally transported to and function in the
phagasome intracellularly to help in degradation and killing phagocytosed microbes or
toxins (Gullberg et al. 1997). Researchers have also shown that the extracellular
secretion occurs from the azurophil granules (Griffiths, 1996; Gullberg et al. 1997)
probably due to cellular contact with bacteria or viruses resulting in an inflammatory
response (Bangalore, 1994) through a process known as “regulated secretion”.
Discovery, Sequence, and Structure of CatG and Chymase
Cathepsin G, also abbreviated as CatG, was first described in 1975 (Dewald et al.
1975; Rindler-Ludwig, 1975), with Starkey and Barrett being the first to purify the
protease from human spleen and thus naming it (Starkey and Barrett, 1976b). CatG
was designated as a member of the HSP family and was found to possess a unique
structure that has been linked to several interesting aspects in the medical field that
warrant additional study. Chymase (chymotrypsin-like enzyme activity) was first
reported in Human Mast cells in 1963 (Lagunoff et al, 1963). Caughey (1991) deduced
the nucleotide sequence and protein structure of human chymase. Both the CatG and
chymase (Caughey et al. 1991) genes were located on chromosome 14, while
azuorcidin, proteinase 3, and Human Neutrophil elastase (HNE) genes were located in
a single locus on chromosome 19 (Gullberg et al. 1997). The nucleotide sequences
coding for the enzymes were obtained for CatG (GenBank M16117), that was
discovered by Salvesen (Salvesen et al. 1987), while chymase’s sequence (GenBank
M64269) was credited to Caughey (Caughey et al. 1991). Information on CatG and
chymase’s structure and function was found in several databases with their 3-D
structure having been previously determined by X-ray diffraction. (CatG, PDB ID#
1CGH, Hof et al. 1996; 1KYN, Greco et al. 2002; and 1AU8, Medrano et al. 1997;
Chymase PDB ID# 1NN6, Reiling et al. 2003; 1KLT, McGrath et al. 1997; and 1PJP,
Pereira et al. 1999).

14

CatG has been found to exist in either a mature (mCatG) or immature (iCatG) form
based upon processing, although the exact reason of the two forms has not yet been
determined. CatG has been found to be synthesized as a 235 amino acid protein in its
full-length or immature form (iCatG) but was found to be processed at both the N and
the C-terminals prior to reaching maturation (mCatG) of 224 residues. The amino acid
sequence of iCatG was first deduced from its cDNA sequence (Salvesen et al. 1987);
however, X-ray crystallography data showed that the mature CatG was missing a Cterminal peptide of 10-12 residues. In addition, the immature form of CatG (iCatG) was
found to have a slightly lower pI of 11.37 than its mature form and a molecular weight of
26757.6 and an extinction coefficient of 0.891 A280/mg/ml (http://www.expasy.org/cgibin/protparam). mCatG was found to have a molecular weight of 25441 with a pI of
11.51 and an extinction coefficient of 0.937 A280/mg/ml (Gasteiger et al. 2005).
Chymase was found to contain 226 residues with a molecular weight of 25029.9, a pI
of 9.60, and an extinction coefficient of 0.957 A280/mg/ml (Gasteiger et al. 2005).
It should be noted that these enzymes were found to have many similarities including
size, isoelectric points, and the first 4 residues of their amino acid sequences. In
addition, their 3D structures (See Figure 1) both contained beta sheets and alpha
helixes in approximately the same regions.

Serine Protease Mechanism of Action
HSPs have been described as possessing a “trypsin-like” activity, as tryptase or
“chymotrypsin-like”, as chymase, or both types of activity as CatG has been shown to
exhibit. These two enzymes have been designated as members of the chymotrypsin
family (Barrett, 1981b) and were proven to have a catalytic triad consisting of the amino
acid residues His 57, Asp102, and Ser 195 (based on the chymotrypsin numbering
system) that catalyzes the cleavage of peptide bonds (See Figure 1). The aspartic acid
residue was shown to act on the histidine to create a dipole that attracted the hydrogen
from the serine residue forming an alkoxide ion, that was found to be a strong
nucleophile. The peptide carboxyl oxygen becomes negatively charged creating an
15
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Figure 1 A3D Structure of Proteases. A) CatG 1CGH B) Chymase 1PJP
with the catalytic triad (His 57, Asp 102 and Ser 195) highlighted in purple.
Beta Sheets are denoted in blue and alpha helices are denoted in red.
Figure adapted from Protein Data Bank. H.M. Berman, J. Westbrook, Z.
Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, P.E. Bourne:
The Protein Data Bank. Nucleic Acids Research, 28 pp. 235-242 (2000).
oxyanion hole, while the alkoxide ion of the serine provides a nucleophilic attack on the
carbonyl carbon of the peptide bond. This, in turn, causes the double bond to be
changed into a single bond, forming a tetrahedral intermediate. The peptide bond was
broken, relieving the negative charge on the oxygen and resulted in an acyl-enzyme
intermediate. The N-terminal section of the cleaved peptide was released with the
donation of a hydrogen ion (+H) to the histidine and a hydroxide ion (–OH) to the
esterified serine by a water molecule that created a second oxyanion hole. The release
of the carboxyl component of the peptide caused the serine’s hydrogen bond to be
released from the histidine’s nitrogen, thus returning the catalytic site to its original
condition.
Binding and Substrate Specificity
Binding must occur between the protease and substrate in order for the cleavage
interaction to take place. Schechter-Bergen nomenclature (Schechter and Berger,
1968) denoted the different locations of the residues of both the substrate and the
enzyme in peptide bond cleavage interactions (Figure 2). The substrate was defined
with “P” with the residues on the N-terminus side of the scissile bond labeled 1, 2, 3…
and the residues on the C-terminus side of the scissile bond labeled 1’, 2’, 3’, etc. The
residues of the protease that formed the binding pocket and interacted with the
substrate residues were denoted with an “S”. The protease residues that interact with
the P1, P2, P3 substrate residues were denoted as S1, S2, S3 and the residues that
16

interact with the P1’, P2’, P3’ substrate residues were denoted as S1’, S2’, S3’. The
scissile bond was designated as the bond between the P1 and P1’ substrate residues
that the protease cleaved.

Figure 2 Schechter-Berger nomenclature for Proteases.
Schechter I. Berger A. (1968) Biochem Biophys Res commun.
32:898-902.

Activity of the two recombinant enzymes was determined by used either a SucVal-Pro-Phe or Suc-Val-Pro-Lys thio benzyl ester substrate in kinetic plate assays.
When the enzyme cleaved the thio benzyl ester substrate, a benzyl-thiol group was
released that, in turn, reacted with the DTNB, releasing the nitro benzoate thiol anion
that produced an intense yellow color with an extinction of 13,600 M-1 cm-1at 405 nm
(See Figure 3).

Figure 3 ThioBenzyl Ester Reaction for CatG
and Chymase. Suc-VPF-Thio benzyl ester is
cleaved by enzyme releasing the Benzyl-thiol
group that forms with DTNB emitting a yellow
color at a wavelength of 405 nm.
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All serine proteases have been shown to function using the same catalytic triad (His,
Asp, Ser), but their differences in specificity have been found to depend primarily on the
structure of the S1 binding pocket of the protease. “Chymotrypsin-like” proteases have
been proven to have a specificity for a substrate with a P1 hydrophobic residue, such as
phenylalanine, tyrosine, tryptophan, leucine, or methionine, while “trypsin-like”
proteases have been found to have a specificity for the positively charged residues
arginines and/or lysines. As a general rule, “chymotrypsin-like” proteases do not cleave
trypsin substrates and “trypsin-like” proteases do not cleave chymotrypsin substrates.
CatG has been proven to be the only known exception to this rule and displayed “dual
specificity” by being able to cleave both chymotrypsin and trypsin substrates (See Table
2).

Table 2 Clustal W Sequence Alignment for CatG, Chymo
(Chymotrypsinogen) and Trypsin. Protein sequences of chymotrypsin
(Chymo), chymase, cathepsin G (CatG), and trypsin were aligned and
compared based on their single letter abbreviations. The active site histidine
(57), aspartic acid (102) and serine (195) are bolded along with glutamic acid
residue a potential secondary binding residue (Higgins D., 1994).

18

Powers et al (Powers et al. 1989) discovered that CatG cleaved both trypsin and
chymotrypsin peptide substrates referred to CatG as a “Janus faced” enzyme and
proposed that Glu226 provided a negative charge to attract a lysine in the P1 position,
indicating that CatG did not possess a second active site for the ”trypsin-like”
substrates. When the crystal structure was determined, researchers (Hof et al. 1996)
found the proximity of the Glu226 to the active site peptide supported the hypothesis of a
secondary S1 site for accepting lysine and arginine (P1) substrates. (Hof et al. 1996;
Polanowska et al. 1998) (See Figure 4). However, Glu226 has not been proven to be the
secondary S1 binding site for trypsin substrates primarily because this enzyme
previously has not been expressed recombinantly.

Glu
O

O-

Val 216

Val 190

C

Chymotrypsin

Trypsin

Cathepsin G

HNE

Figure 4 Cathepsin G and HNE Specific Binding Pockets.
The enzymes chymotrypsin, trypsin, and elastase binding
pockets are shown with trypsin having a glutamic acid (glu)
residue. Elastase has 2 valines that limit only linear residues
entering the pocket.

CatG has been found to cleave many biological proteins after bulky aromatic
residues such as phenylalanine, histidine, isoleucine, valine and tyrosine or after
positively charges residues such as lysine and arginine
(http://www.hprd.org/protein/00289?selectedtab=PTMs; Saravana, 2005). CatG interacted in vitro
with Thrombospondin I (Hogg et al. 1993a); (Hogg et al. 1993b), Kininogen (Selim et al.
2001), Protease inhibitor 13 (Mitsudo et al. 2003), Coagulation Factor V (Camire et al.
1998), Syndecan 1 (Kainulainen et al. 1998), Integrin (Molino et al. 1993), and beta
thromboglobulin (Cohen et al. 1992). CatG interacted in vivo with alpha 1
antichymotrypsin (Gibson, 1999) and PAR3 (Cumashi et al. 2001). Chymase has
“chymotrypsin-like” activity allowing it to cleave after bulky aromatics (FLYW).
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Medical Relevance
CatG and chymase have been found to play important roles in many biological
processes and conditions. CatG has been associated with blood clotting and was
proven to cleave coagulation Factor X and Factor V (Camire et al. 1998). The protein
also was found to have the sequences IIGGR and HPQYNQR that have been
considered to be antimicrobial agents toward Neisseria gonorrhoeae and
Staphylococcus aureus (Odeberg et al. 1975) even though its active site was inhibited
(Shafer et al. 1996; Shafer et al. 1991; Bangalore et al. 1990). The two antimicrobial
sequences were determined by purifying neutrophil CatG and digestion of the enzyme
into fragments. The fragments were then purified and the two antimicrobial sequences
corresponding to residues 1-5 (N-terminus IIGGR) and 77 - 83 (HPQYNQR) were
identified. Bangalore et. al. (1990) also synthesized the corresponding antimicrobial
sequences and showed that they were also bacteriacidal. CatG was also found to
degrade the flagella of Pseudomonas aeruginosa (Lopez-Boado et al. 2004) and to
cleave and inactivate the neutrophil chemoattractants tumor necrosis factor-alpha (TNFα) (Scuderi et al. 1991), interleukin-1 (IL1) (Hazuda et al. 1990), and interleukin 8 (IL8)
(Padrines et al. 1994). CatG was shown to produce apoptosis in cardiomyocytes by
activation of caspase 3 (Sabri et al. 2003) and convertsion of angiotensin I into
angiotensin II (Reilly et al. 1982). DNA fragments of 30 bp have been shown to bind
CatG with a Kd of 8.5nM; furthermore this complex decreases the inhibition of a-1proteinase inhibitor by 3190 fold (Duranton et al. 2000b). As Duranton explains, “DNA
thus renders CatG virtually resistant to inhibition by these irreversible serpins” and
makes CatG a major player in inflammatory lung disease (Duranton et al. 2000a).
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Renin
ACE
ANGIOTENSINOGEN-------------> ANGIOTENSIN I ---------------> ANGIOTENSIN II
Renin cleaves after the Leu
ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE-HIS-LEU

ACE cleaves after the Phe
ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE
HIS-LEU

Figure 5 Conversion of Angiotensinogen to Angiotensin II. This Figure
depicts the event that Angiotensinogen is converted into Angiotensin I by the
enzyme renin and then into Angiotensin II by the enzyme ACE. Renin
cleaves after the amino acid Leu, while ACE cleaves after Phe. This classic
conversion mechanism has also been found to occur from reactions of CatG
or chymase.
Chymase was found to have several medically related functions such as degradation
of HDL (Lee et al. 2002), production of apoptosis in rat smooth muscle (Leskinen et al.
2006) and the conversion of angiotensin I into angiotensin II (Caughey et al. 2000).
Angiotensinogen was converted by renin into angiotensin I by cleavage following a
leucine residue and into angiotensin II with cleavage after a phenylalanine amino acid
by ACE (See Figure 5). CatG and chymase can also produce the same conversion
effects with their proteolytic abilities.
Experimental Purpose
The overall objective of this work was to clone and express the active enzymes
chymase (EC 3.4.21.39) that has chymotrypsin-like activity and cathepsin G (EC
3.4.21.20) that possesses both trypsin-like and chymotrypsin-like activity using the
Pichia pastoris expression system. Recombinant CatG was expressed in two different
forms, an immature full length CatG protein (iCatG) and a mature protein (mCatG) that
had 11 amino acids eliminated from the C terminus. A mature, native form of CatG
(nCatG), previously isolated from neutrophils, was used as a positive control during
characterization studies. It has been hypothesized that the purpose of the C-terminal
extension was to inactivate the protease prior to its transport to the granule to allow cell
survival (Garwicz et al. 1998). However, it was not known whether the C terminus of
21

iCatG may affect its catalytic activity because this protein has not been expressed in
sufficient quantities to allow isolation and careful characterization study prior to this
research. A hypothesis of this dissertation was that the presence of the 11 amino acid
C-terminus of CatG does not prevent catalytic activity but existed for a different role,
such as cell surface attachment or reduced SERPIN inhibition.
An active recombinant form of CatG, either in its immature or mature form, has not
been previously expressed, presumably due to the protease activity against the
intracellular machinery of the host cell. Garwicz was able to produce an inactive
enzyme that had both its catalytic site mutated and its propeptide removed, with the
protease still being transported to the granule and able to bind to aprotintin after further
processing in the granule (Garwicz et al. 1998). However, when an active form of the
same enzyme that had its propeptide removed was expressed, it resulted in unviable
cells (Garwicz et al. 1998). Garwicz also proved that the protease was processed in the
granule and not in golgi through disruption of the organelle with Brefeldin A that
disassembles the apparatus (Garwicz et al. 1998). In previous studies Garwicz also
mutated the N-glycosylation site to eliminate the mannose-6-phosphate tag as a means
for transportation (Garwicz et al. 1995).
Incorporating the Invitrogen Easy Select Expression System allowed the
enzymatically active protease to be produced without further processing as it was
attached to the Kex2 cleavage site. In addition, the alpha-secreting factor allowed the
protease to be secreted extracellularly, thus preventing damage to the host and allowing
activity to be determined by kinetic assays. Used the homologous recombination of the
yeast expression prevented the CatG sequence from being removed from the host cell
genome as can be the case with a plasmid. This system was also beneficial in that
Pichia has an optimal growth pH of 5, while CatG was found to be less active at the
same pH thus reducing any potential catalysis of protein. The ingredients for media
were also minimal for this expression system and the viral threat has been removed
through recombinant expression as the enzyme was not isolated from tissue. The
zeocin resistance gene also proved to be beneficial in that it allowed selection of
positive transformants for both E. coli and Pichia.
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The expression of active recombinant CatG in both its immature and mature
forms by this expression system now may allow confirmation of other issues such as the
secondary binding pocket, C terminal processing, and function.
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SYNOPSIS
Human mast cell chymase (EC: 3.4.21.39) has been shown to be a chymotrypsinlike serine protease stored in and released from mast cell granules. This enzyme has
been expressed in Pichia pastoris via homologous recombination of the cDNA coding
for the mature active chymase into the Pichia genome. Cells producing the highest
levels of recombinant human chymase (rhChymase) were selected by activity screening
and they were grown in a fermentor. Methanol induction resulted in the secretion of
active chymase into the Pichia growth media and increasing levels of enzyme were
detected in the media for 5 days. Active enzyme was purified from the culture media
with a 22% yield of activity via a simple two-step procedure, using hydrophobic
interaction chromatography followed by affinity chromatography on immobilized heparin.
The major peak from the heparin-column contained a single band of 30.6 kDa on SDSPAGE. The purified rhChymase was 96% active and the yield was 2.2 mg per liter of
growth media.

Key words: Active, Chymase, Fermentation, Heparin, Human, Secretion
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INTRODUCTION
Chymase (EC: 3.4.21.39) has been proven to be a chymotrypsin-like serine
proteinase found in the cytoplasmic granules of some human mast cells (Irani and
Schwartz, 1994), and stored and released as an active enzyme when mast cells
degranulate (Sayama et al. 1987; Schechter et al. 1994; Welle, 1997). Chymase has
been shown to have multiple functions, with its ability to convert angiotensin I to
angiotensin II (Reilly et al. 1982) receiving considerable attention. Human skin tissue
served as the initial source of mast cell chymase (Schechter et al. 1983). There have
been several reports on the expression of recombinant human mast cell chymase
(rhChymase). Mammalian cell lines COS1 (Urata et al. 1993) and CHO-K1 (Ferry et al.
2001) have been used to produce recombinant human chymase (rhChymase) in the
pro-enzyme form. Escherichia coli expression systems yielded unglycosylated protein
requiring refolding and activation with enterokinase (Takai et al. 2000; Wang et al.
1995). Bacillus subtilis was used to produce active rhChymase in the culture media that
lacked glycosylation (McGrath et al. 1997). The baculovirus insect expression system
yielded the highest amounts of rhChymase in a zymogen form requiring activation with
enterokinase (Suzuki et al. 2002; Wang et al. 1998) or dipeptidyl peptidase I (McEuen et
al. 1998). Pichia pastoris was found to secret active enzyme (Nakakubo et al. 2000a)
and to accumulate inactive rhChymase in the cells (Nakakubo et al. 2000b). In this
report we have described an improved Pichia pastoris system for the stable expression
of active rhChymase and purification of the enzyme from the growth media.
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EXPERIMENTAL PROCEDURES
Materials
Succinyl-Ala-Ala-Pro-Phe-p-Nitroanilide (Suc-AAPF-pNA S-7388), goat Antimouse IgG (Fab specific) conjugated to alkaline phosphatase (A-2179), antifoam B,
and octyl glucoside (O-8001) were obtained from Sigma Chemicals. Western Blue™,
NotI, BstXI, and XhoI were Promega products. MES, glycerol, octyl glucoside,
ammonium sulfate, sodium azide, and sodium chloride were purchased from Fisher
Scientific. Tosopearl butyl 650-M and AF-Heparin resins were obtained from Tosohaas.
NuPAGE SDS gels (12% acrylamide) pre-cast with Bis-Tris buffer, NuPAGE MOPS
buffer (20X), True Blue pre-stained protein standards, Simply Blue coomassie stain, and
Pichia pastoris EasySelect Pichia Expression Kit were purchased from Invitrogen. The
GelCode Blue Stain was purchased from Pierce. DeepVent DNA polymerase and
Peptide N-glycosidase F (PNGase F) were obtained from New England Biolabs.
Competent JM109 E. coli cells were produced by the method of Inoue et al. (Inoue et al.
1990). Micro-titer 96-well half-diameter plates (Product Number 3695) were obtained
from Corning. Recombinant Eglin C was graciously provided by H.P. Schnebli (CibaGeigy). The full-length cDNA in the pVL1392 vector (Invitrogen) was generously
provided by Dr. George Caughey (UCSF). The chymase specific CC1 mouse
monoclonal Ab was generously provided by Dr. Andrew Walls (Southampton).
A 10X Yeast Nitrogen Base (YNB) solution was prepared by dissolving 134 g of
Yeast Nitrogen Base with ammonium sulfate but without amino acids in 1 L of dionized
water and filter sterilized. A 500X Biotin solution was prepared by dissolving 20mg in
100ml of deionized water and filter sterilized. The Trace Metals Solution contained 6 g
CuSO4·5H2O, 0.08 g NaI, 3 g MnSO4·H2O, 0.5 g CoCl2, 20 g ZnCl2, 0.02 g H3BO3,
Na2MoO4·2H2O, FeSO4·7H2O, 4 ml of 6 N H2SO4 and 0.2 g Biotin per liter that was filter
sterilized. The basic salts fermentation media contained 0.93 g CaSO4·2H2O, 18.2 g
K2SO4, 14.9 g MgSO4·7H2O, 4.13 g KOH, 4.3 g NH4Cl, 26.7 ml H3PO4, 40 ml glycerol,
and after sterilization 4.6 ml of the Trace Metals solution were added. Agar Yeast
Extract Peptone Dextrose Medium plates with Zeocin (YPDS) contained 1% yeast
extract, 2% peptone, 2% dextrose (glucose), 1 M sorbitol, 2% agar and 100 µg/ml
Zeocin. Buffered Glycerol-complex Medium (BMGY) media was prepared by dissolving
10 g yeast extract and 20 g peptone in 700ml of water followed by sterilization to that
was added 100 ml of 1 M K2HPO4 pH 6.0, 100 ml 10XYNB, 2 ml 500X Biotin and 100 ml
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10% glycerol. Buffered Methanol-complex Medium (BMMY) media was the same as
BMGY with 50 ml of methanol in place of the glycerol.
Construction of pPICza-rhChymase
Recombinant human chymase (rhChymase) was engineered and cloned into the
pPICza vector for expression in Pichia pastoris strain X-33. The full-length human
chymase cDNA was amplified and engineered via PCR using the primers shown in
Figure 1. PCR removed the signal and pro-peptides and added a Kex2 protease
cleavage site just prior to the region coding for the N-terminal of the active enzyme.
These primers also added restriction sites for XhoI at the 5’ end and for NotI at the 3’
end, and a stop codon at the 3’ end. The PCR product was analyzed on a 3% Nusieve
agarose gel. After digestion with XhoI and NotI the PCR product was ligated into the
similarly cut pPICza vector that had been gel purified and isolated using a Qiagen kit.
The ligation mixtures were used to transform competent JM109 E. coli. Positive
colonies were selected on low-salt LB plates with 25 µg/ml of Zeocin. Only 1 of the 10
positive colonies contained the chymase gene insert based on the analysis of plasmid
#6 DNA on 1% agarose gels after digestion with XhoI. PCR of plasmids #6 and #10
using the chymase primers yielded a product of 800 bp with plasmid #6, whereas
plasmid #10 was negative as expected. Sequencing of this rhChymase-pPICza
plasmid (#6) using 5’alpha factor and 3’AOX1 specific primers (Invitrogen), proved that
the correctly engineered chymase gene was in-frame with the alpha factor initiation
codon and that the chymase coding region ended with a stop codon. The rhChymasepPICza DNA (3 µg) lineraized with BstXI was used to transform the X-33 strain of Pichia
pastoris that had been made chemically competent using the EZComp Reagents. After
growing the transformed Pichia-X-33-rhChymase on YPDS (yeast extract peptone
dextrose medium) 1% yeast extract, 2% peptone, 2% dextrose (glucose), 1 M sorbitol,
2% agar plates containing 25 µg/ml Zeocin for 4 days, 20 positive colonies were picked
and re-screened on YPDS-Zeocin plates. Of the 20 colonies 16 were again positive
and these were screened for chymase expression by first growing 10 ml cultures in
glycerol-containing BMGY media overnight at 30 oC with shaking. The cells were then
switched to methanol-containing BMMY media and cultured overnight at 30 oC with
shaking. After centrifugation at 3000 x g for 5 minutes the media was assayed using 50
µM Suc-AAPF-pNA as the substrate. Three colonies (#2, #8, & #10) produced the most
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chymase activity, but colony #10 had a little more activity and was used for expression
in a fermentor.

Figure 6 Schematic of rhChymase Genetic Engineering.
Diagram shows the expression product from the starting Met of
alpha factor to the chymase N-terminus. The Kex2 processing sit is
marked with an arrow. Primer sequences, restriction sites (italics),
and the codes amino acids are also shown.
Figure 6 has depicted a schematic diagram of the genetic engineering showing the
expression product from the starting Met of alpha factor to the chymase N-terminus,
with the Kex2 processing site marked by an arrow. Primer sequences, restriction sites
(italics), and the coded amino acids have also been shown. The pePICza vector
contains sequences homologous to the alcohol oxidase 1 (AOX1) gene in Pichia and
the transformation results in homologous recombination of the engineered sequences
under the control of the AOX1 gene, producing a stable cell line. The Pichia pastoris X33-chymase grew well on media containing glycerol as the carbon source, but when the
carbon source was changed to methanol the AOX1 gene was turned on and growth was
slowed. Pichia pastoris X-33-chymase secreted the alpha factor- Kex2-chymase
protein because the alpha factor contained secretion recognition sequences. Because
the Pichia pastoris contained the Kex2 protease, this enzyme cleaved at the engineered
Kex2 cleavage site, freeing it from alpha factor and releasing active chymase into the
media.
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Fermentation
To obtain enough rhChymase for purification, Pichia pastoris- X-33-chymase was
grown using a New Brunswick BioFlo 110 fermentor with a 7-liter vessel. The colony
producing the highest level of rhChymase activity, designated X33-rhChymase, was
grown 24 hours in a 0.5 L baffled shaker flask containing 200 ml of BMGY media.
When this culture reached an A600 of 6.6, it was used to inoculate 2500 ml of basal salts
media with glycerol media in the fermentor. Air was pumped through the stirred culture
to maintain the dissolved oxygen level at 40% by varying the stirring rate from 2001,000 RPM and temperature was maintained at 30oC. The pH was maintained at 5±0.2
by pH probe controlled addition of 7.5% NH4OH or 8% H2SO4. The culture was fed 1
ml/min of 50% glycerol containing 12 ml/L Trace Metals Solution. After 46.5 hours the
A600 was 220 and the cells were separated from the media by centrifugation at 3000 x g
for 30 minutes and re-suspended in BMMY and returned to the fermentor. After 30
minutes, 100% methanol containing 12 ml/L of Trace Metals Solution was added at a
rate of 1ml/hour using a peristaltic pump. Samples were removed daily and assayed for
chymase activity. The media was harvested on day 5, after 120 hours of induction and
separated from the cells by centrifugation at 10,000 x g for 30 minutes. The media
(3280 ml) was stored at -20 oC until it was used for purification
In Vitro Enzymatic and Protein Assays
Chymase activity was measured using 0.5 mM succinyl-Ala-Ala-Pro-Phe-pNitroanilide (Suc-AAPF-pNA) in 0.1 M Hepes, 1 M NaCl, 10% glycerol, 0.1 mg/mL
Heparin, 0.01% Triton X-100, 0.02% Sodium Azide, pH 7.5. Assays were performed in
Corning 96-well half diameter plates with 25 µL samples. Reactions were started by
adding 25 µL of 1 mM substrate in the assay buffer. Kinetic rate data were obtained by
following product development at 405 nm using a BIO-TEK Instruments EL 312e with
KC Junior software to measure initial velocities. Rate data were collected every 10
seconds for a total of 10 minutes at 22 – 25 oC. Linear regression fits to the initial
portion of the rate curves had r2 values of 0.99 or higher. A unit of enzyme activity was
defined as an increase of 1 absorbance unit at 405 nm per minute at room temperature.
Protein was measured by A280 and the conversion to mg/ml was based on the A280
value 0.952 for a 1% solution calculated from the amino acid composition of the active
enzyme (Pace et al. 1995). For the determination of Km and kcat kinetic constants with
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the Suc-AAPF-pNA substrate the buffer used was 0.45 M Tris-HCl, 1.8 M NaCl, 9%
DMSO, pH 8.0 (Schechter et al. 1997) and regular microplates with full-sized wells were
employed to assure adequate mixing. The substrate range was 0.1 – 7 mM and initial
rate data were analyzed by non-linear regression of a plot of rate versus substrate
concentration with fitting to a hyperbolic curve using Sigma Plot.
Electrophoretic Analyses
Protein samples of equal A280 were concentrated and de-salted via TCA precipitation
in the presence of 0.02% deoxycholate (Brown et al. 1989) for SDS-PAGE. After
washing the precipitated protein with 10% TCA followed by 1% TCA, 3 acetone washes
were used to remove the TCA. Air dried samples were dissolved in NuPage LDS
Sample Buffer (Invitrogen) with 50 mM dithiothreitol as the reducing agent. Samples
were analyzed on NuPAGE 12% Bis-Tris pre-cast gels (1.0 mm X 10 well) using
NuPAGE MOPS buffer. Following electrophoresis at 200 volts for 45 minutes protein
bands were stained with GelCode Blue (Pierce) coomassie stain. Imaging was
accomplished with an Alpha Innotech Alpha Imager and software, except for the
Western blot that was imaged on a flat bed scanner. For the analysis of expression in
media samples 5 ml from each time point were first bound to 1 ml of AF-heparin resin
followed by batch elution with 0.5 ml of 1 M NaCl. Samples were concentrated and
desalted via TCA precipitation.
For Western blot analyses, samples were subjected to SDS-PAGE under reducing
conditions and electro-blotted onto nitrocellulose, blocked with 1% BSA in 10 mM TrisHCl, 150 mM NaCl, 0.05% Tween 20, pH 8.0 (TBST), and probed with anti-human
chymase mAb, clone CC1 1:5000 in TBST. Then the blots were incubated with a
1:10,000 dilution of goat Anti-mouse IgG (Fab specific) conjugated to alkaline
phosphatase in TBST and developed with Western Blue™ alkaline phosphatase
detection reagent.
Deglycosylation
Both rhChymase peaks A and B off the heparin column were subjected to PNGase F
digestions according to the manufacturer’s protocol. Briefly, the chymase peaks (0.012
A280 units of each) were denatured and desalted via TCA precipitation. Protein pellets
were dissolved in the deglycosylation denaturing buffer containing 0.5% SDS and 1%
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beta-mercaptoethanol and heated at 100 oC for 10 minutes. Samples were then made
50 mM in sodium phosphate pH 7.5 with 1% NP-40 and incubated with 1000 units of
PNGase F at 37 oC for 24 hours. The reaction was stopped by adding SDS-PAGE
sample buffer and heating to 100 oC for 5 minutes prior to analysis on 12% a NuPAGE
gel. Protein bands were detected by staining with Simply Blue coomassie stain
(Invitrogen).
Eglin C Active Site Titration
Recombinant Eglin C, a leech derived inhibitor of chymase with a molecular weight
of 8222, was used to measure the activity of the purified rhChymase. A known and
constant amount of rhChymase (5.5 pmol) was incubated with increasing amounts of
Eglin C in microplate wells followed by enzyme assays of the residual chymase activity.
A stock solution containing a known amount of Eglin C was prepared based on its A280
extinction coefficient of 0.934 for a 0.1% solution. Because each mole of Eglin C
inhibits 1 mole of chymase the resulting titration plot provides a measure of the absolute
activity of the rhChymase.
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RESULTS and DISCUSSION
Expression Kinetics
Cell-free supernatants were collected at 0, 24, 48, 96 and 120 hours post-induction
and analyzed by SDS-PAGE (Figure 7), Western blotting (Figure 8), and assayed for
chymase activity (Figure 9). SDS-PAGE analysis of the heparin-binding proteins in the
media showed an increasingly darker band at approximately 33 kDa. Western blotting
using a monoclonal to chymase showed no reaction prior to methanol induction and an
increasingly positive band corresponding to the expected molecular weight of
approximately 32 kDa (Figure 7) after induction. As expected, no chymase activity was
detected in the Pichia pastoris X33-rhChymase media prior to induction, whereas
following induction, chymase enzymatic activity increased up to 120 hours post
induction (Figure 8). Taken together these data show that Pichia pastoris X33rhChymase expressed active rhChymase following induction.

Figure 7 SDS-PAGE of Fermentation Media. Media (5
ml) taken at different times was analyzed by SDS-PAGE
with reduction. Samples had been bound to AF-heparin
column material and prepared as described in Methods.

.
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Figure 8 Induction of Immuno-reactive
rhChymase. Western blot of fermentation
media using a monoclonal antibody.
Samples were prepared by TCA
precipitation.

Figure 9 Induction of rhChymase Activity.
Secreted chymase activity was measured each day
in the growth media starting with Day 0, just prior to
the addition of methanol. Chymase activity was
assayed using 50 µL of media in a standard plate
with a total volume of 100 µL.

Purification
Cell-free media was obtained by centrifugation at 10,000 x g for 30 minutes and
stored at -20 oC for 3 months. Upon thawing the media was made 2 M in ammonium
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sulfate by slowly adding the solid while stirring. After the ammonium sulfate was
dissolved, the media was centrifuged at 21,000 x g for 30 minutes, resulting in only a
minor pellet and a clear supernatant fraction. A 150 ml sample of this media was then
applied to a TosoHaas 650M butyl hydrophobic interaction column (2.5 x 8.5 cm; 41.7
ml) equilibrated in10 mM MES, 10% glycerol, 0.01% octyl glucoside (OG), 2 M
ammonium sulfate (AS), 0.02% sodium azide, pH 6.0. After washing extensively with
the equilibration buffer, rhChymase was eluted with 0.5 M ammonium sulfate, 10 mM
MES, 10% glycerol, 0.01% OG, pH 6.0 at a flow rate of 2 ml per minute. Fractions were
collected at 1.5 min intervals, yielding ~3 mL/fraction (Figure 10). Pooled fractions (1224) were made 1 M in ammonium sulfate and concentrated in an Amicon stirred cell to

Figure 10 Butyl Column Chromatography. Media
(150 ml) that had been made 2 M in AS was applied to
a TosoHaas 650 M butyl hydrophobic interaction
column (2.5x8.5 cm; 41.7 ml) equilibrated in 10 mM
MES, 10% glycerol, 0.01% OG, 2 M AS, 0.02% NaN3,
pH 6.0. After washing extensively with the
equilibration buffer, rhChymase was eluted with 0.5 M
AS, 10 mM MES, 10% glycerol, 0.01% OG, pH 6.0 at
a flow rate of 2 ml per minute. Fractions (3 ml) were
collected at 1.5 min intervals and 2 µL of each were
assayed for activity. Fractions 12-24 were pooled for
chromatography on the heparin column.
23 ml. This sample was diluted 10 fold with deionized water and loaded onto a
TosoHaas-Heparin-AF column (1.5x13 cm; 23 ml) equilibrated with 10 mM MES, 0.2 M
NaCl, 10% glycerol, 0.01% OG, 0.02% NaN3, pH 6 and washed with this buffer until the
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A280 was essentially zero. The bound rhChymase was eluted with a 150 ml linear
gradient from 0.2 – 0.75 M AS in the same buffer at a flow rate of 2 ml per minute,
collecting 3ml fractions. As shown in Figure 11, two peaks of chymase activity were
obtained with the second peak containing most of the activity and being separated from

Figure 11 Heparin Column Chromatography. The
rhChymase pool off the Butyl column was applied to a
TosoHaas-Heparin-AF column (1.5x13 cm; 23 ml)
equilibrated with 10mM MES, 0.2 M NaCl, 10% glycerol,
0.01% OG, 0.02% NaN3, pH 6. The bound rhChymase
was eluted with a 150 ml linear gradient from 0.2 - 0.75
M AS in the same buffer at a flow rate of 2 ml per
minute. Fractions of 3 ml were collected and assays
were performed on 2 µL of each fraction. Activity peaks
A (25-33) and B (34-43) were pooled separately and
analyzed.

the major A280 peak. Fractions 35-44 were pooled and concentrated to 2.5 mL using an
Amicon stirred cell with a 10 kDa Pall Omega membrane. The A280 of this solution was
0.13 that was calculated to be equivalent 0.137 mg/mL for a total protein yield of 342
micrograms from 150 mL of media. The data from 1 purification procedure have been
shown in Table 1. The yield of pure rhChymase in peak B off the heparin column from 3
purifications averaged 2.23 ±0.2 mg per liter of Pichia media. SDS-PAGE analysis of
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both peaks showed that Peak A had a much fainter band at 33 kDa than Peak B (Figure
12). While

Figure 12 SDS-PAGE Analysis of Purified and
Deglycosylated rhChymase. SDS-PAGE with reduction
and deglycosylation of Heparin Peaks A and B. Lanes
labeled NO are untreated Peaks A and B from the Heparin
column. Lanes labeled YES were deglycosyalted with
PNGaseF. The lane labeled PNGaseF contained only the
PNGaseF enzyme.

both peaks contained a faint band at 58 kDa, Peak A also contained a broad diffuse
band from 40 to 58 kDa. The yield of activity in Peak B was 22% with this material
having been purified more than 1000 fold (Table 3).
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Purification Data
Total
Step

Media
Butyl Column
Heparin Peak B

Total

Specific

Yield

Protein

Activity

Activity

%

(A280)

(units)

(units/A280)

1548

891.6

0.576

87

527.1

6.06

59

199.7

614.5

22

0.325

100

Table 3 Purification Data. A table is displayed detailing each
of the 3 purification steps. The A280 of each step is seen in
Column 2. Column 3 shows total activity with the specific
activity (units/A280) in Column 4; and the % Yield from
purification in Column 5.

Deglycosylation
Both rhChymase peaks A and B were treated with PNGase F to remove Asn-linked
carbohydrate and analyzed on SDS-PAGE (Figure 12). Comparison of the bands in
lanes treated with PNGase F (YES) with the untreated control samples (NO) show that
the products were glycosylated. Peak A bands decreased to two bands of 31.5 and
25.3 kDa that stained more intensely. The Peak B band at 58 kDa was reduced to 51.4
kDa and the major band at 33 kDa was reduced to 25.3 kDa. The bands at 25.3 kDA in
both samples probably represent the deglycosylated rhChymase, that has a calculated
molecular weight of 25.03 kDa. The identity of the 31.5 kDa band in Peak A after
deglycosylation was unknown, but it may be a contaminant or possibly rhChymase with
Ser or Thr-linked carbohydrate, resistant to PNGase F. The Peak B band at 51.4 kDa
may represent a small amount of dimeric rhChymase.
Activity Measurement
To determine the percentage of rhChymase in Peak B that was active, samples
were incubated with increasing molar ratios of Eglin C, a tight binding inhibitor. As
shown in Figure 13, chymase activity decreased with increasing Eglin C molar ratios
and linear regression of the data intersected at 0.96 mole of Eglin C per mole of
rhChymase, indicating that the rhChymase was 96% active.
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% Chymase Activity
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Eglin C/rhChymase (mol/mol)
Figure 13 Active Site Titration with Eglin C. rhChymase was
incubated with increasing molar ratios of Eglin C followed by
enzyme assays of the remaining rhChymase activity as
described. Linear regression of the data (r2 = 0.92) intersected
at 0.96 mole Eglin C per mole of rhChymase. Error bars
represent the standard deviation of the mean of triplicate assays.

Kinetic analysis of the purified rhChymase with the Succinyl-Ala-Ala-Pro-Phe-pNA
substrate yielded a Km of 2.96 mM and a kcat of 17.5 sec-1 resulting in a calculated
kcat/Km catalytic efficiency constant of 5,912 M-1s-1. This Km value was lower than the
value of 5.93 mM previously reported for Pichia expressed rhChymase (Schechter et al.
1997), but higher than the Km of 0.95 mM reported for natural human skin chymase.
The kcat we observed was lower than the 50 sec-1 reported for natural human skin
chymase for this substrate. These kinetic differences were not considered to be
unreasonable and could be due to differences in glycosylation.
Concluding Remarks
Presented data clearly demonstrate the stable expression of rhChymase by
transformed Pichia pastoris with secretion into the media. Normally, proteases are
expressed as zymogens that require activation. The addition of a Kex2 site prior to the
amino terminus of the chymase used the ability of the Pichia to activate the translational
product. The activation of the expressed enzyme via an additional step was avoided
when this approach was used. A simple two-step purification protocol was developed
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that yielded highly purified and highly active rhChymase. An amount of 2.2 mg of
rhChymase was obtained from a liter of media, that represented a considerable
improvement in the yield of rhChymase compared to other methods. While a number of
different systems have been used to produce rhChymase (Table 4), only expression in
Baculovirus systems produced greater amounts of enzyme. However, the Pichia
system has the considerable advantage of producing active enzyme, rather than a
zymogen form that requires activation. Additionally, the rhChymase produced in Pichia
was found to be structurally similar to natural chymase,

Comparison of Various rhChymase Expression Systems

System

Product

mg/L

Reference

COS

Pre-pro-

ND

Urata et al., 1993

CHO-K1

Pro-

0.800

Ferry et al., 2001

E. coli

Ub-Ek-

0.125

Wang et al., 1995

E. coli

His-tag-Ek-

ND

Takai et al., 2000

B. subtilis

active

0.500

McGrath et al., 1997

Baculovirus

Pro-

0.960

McEuen et al., 1998

Baculovirus

Ub-Ek-

3

Wang et al., 1998

Baculovirus

hemolymph-Ek-
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Suzuki et al., 2002

P. pastoris

active/media

0.190

Nakakubo et al., 2000

P. pastoris

inactive/cellular

ND

Nakakubo et al., 2000

P. pastoris

active/media

2.2

Present report

Table 4 Comparison of Various rhChymase Expression
Systems. A table is displayed containing the different
expression systems used in Column 1. Column 2 details their
generated product; with the final purified quantity displayed in
Column 3; and the Researcher in Column 4.
in that both the natural and recombinant proteins were glycosylated. The stable
expression of active rhChymase in Pichia pastoris at increased levels will facilitate
further study of this interesting serine protease. Isolation of rhChymase from Pichia
eliminates the hazards of working with human tissues and greatly increases the amount
of available enzyme. In particular, rhChymase can be used as a primary standard in
immunological assays and for comparison with other natural and recombinant
proteases.
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SYNOPSIS
Human mast cell cathepsin G (EC 3.4.21.20), that had not previously been
expressed as a recombinant protein, was found to be a “Janus faced” serine protease
possessing both a chymotrypsin-like and a trypsin-like activity stored in and released
from mast cell granules and in neutrophils. This enzyme was expressed in Pichia
pastoris via homologous recombination of the cDNA coding for the active immature
(iCatG) and mature (mCatG) forms into the Pichia genome. Cells producing the highest
levels of recombinant human CatG (rhCatG) were selected through kinetic activity
screening during a pilot expression test. Pichia colonies of both forms of CatG, that
displayed superior enzyme production, were induced for 4 days and stabilized with
dextran sulfate in the media. The proteases were partially purified using ultrafiltration.
A major peak was detected on SDS-PAGE gel at 26 kDa with the sequence being
confirmed as iCatG through MALDI-TOF Mass fingerprinting. Kinetic activity assays
were performed on both iCatG and mCatG using two different substrates Suc-APF-SBzl
and Suc-APK-SBzl that presented similar Vmax. Inhibition studies using TPCK, TLCK,
Bowman-Birk, and Eglin C eliminated the dual activity of both forms of rhCatG
confirming the dual activity.
Key words: Active, Cathepsin G, Dextran Sulfate, Human, Secretion, Protease, Mast
Cell
Abbreviations: Recombinant human cathepsin G, rhCatG; Recombinant Immature
cathepsin G, iCatG; Recombinant mature cathepsin G, mCatG; native cathepsin G
purified from neutrophils, nCatG; Serine Protease Inhibitors, SERPINS; Suc-VPF-SBzl,
succinyl- Valine-Proline-Phenylalanine thiobenzyl ester; Suc-VPK-SBzl, succinylValine-Proline-Lysine thiobenzyl ester; polymerase chain reaction (PCR); SDS-PAGE,
sodium dodecylsulfate polyacrylamide gel electrophoresis; Tosyl phenylalanyl
chloromethyl ketone (TPCK); Tosyl-L-lysin-chloromethyl ketone (TLCK); DTT,
dithiothreitol; Hepes, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic; IC50, Inhibitory
concentration for 50% reduction of activity.
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INTRODUCTION
Human mast cell cathepsin G (CatG; EC 3.4.21.20), that had not previously been
expressed in recombinant form, has been named a “Janus faced” serine protease
possessing both chymotrypsin-like and trypsin-like activities. CatG had been found in
both neutrophils (Barrett, 1981a) and in mast cell granules(Schechter et al. 1990).
Although the CatG mRNA (NM_001911) had been found to code for an active enzyme
of 235 amino acids, only a mature form (mCatG) of approximately 224 residues has
been isolated from neutrophils and studied. X-ray crystal structures show that mCatG
had lost 10 to 12 residues from the C-terminal based on Protein Data Bank IDs 1KYN
and 1CGH. Although they were shown to possess similar molecular weights and
isoelectric points, the exact reason for C-terminal processing has not been discovered.
Neutrophil elastase also undergoes C-terminal processing to remove 20 residues and
elimination of this processing has been linked to cyclic neutropenia (Horwitz et al.
2004). Although CatG has been generally regarded as a chymotrypsin-like protease
cleaving at hydrophobic residues, it has also been shown to cleave synthetic substrates
after lysines (Powers et al. 1989), that has been confirmed in this laboratory
(unpublished data). Additionally, the crystal structure of CatG showed a Glu at position
226 (chymotrypsinogen numbering) situated at the bottom of the S1 specificity pocket
(Hof et al. 1996) that could form an ionic bond to lysine (Hof et al. 1996). Hydrophobic
residues, such as phenylalanine, bind at the entrance of the S1 pocket, but they do not
fully occupy the S1 pocket as research has concluded for normal chymotrypsin-like
proteases. Hof et al. (1996) termed CatG a “Janus-faced” enzyme because of the dual
specificity for trypsin-like and for chymotrypsin-like substrates. The inability to fully bind
chymotrypsin-substrates may explain the slow reaction kinetics of CatG with
chymotrypsin substrates (Powers et al. 1989). This dual specificity was confirmed using
p-nitroanilide substrates (Polanowska et al. 1998). CatG’s dual specificity allows
cleavage of many biological proteins either after bulky aromatics (F, H, I, V, Y) or
positively charged (L and R) residues of different proteins. Although first purified from
human tissue and characterized in 1976 (Starkey and Barrett, 1976a), CatG had not
been produced in a recombinant form prior to this research. There have been several
factors that have made CatG impossible to express as a recombinant protein, including
its bactericidal activity (Reeves et al. 2003; Shafer et al. 1991) and its high isoelectric
point that had recently been shown incorrectly to be a negative factor for protein
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expression in Pichia pastoris (Boettner et al. 2007). Garwicz’s attempt at expression of
active CatG, with its propeptide deleted, resulted in non-viable cells (Garwicz et al.
1998) upon transformation of RBL-1 cells; however, they expressed an inactive mutant.
Salvesen found that CatG (and neutrophil elastase) are “therefore, transiently present
as zymogens, presumably to protect the biosynthetic machinery of the cell from
adventitious proteolysis (Salvesen and Enghild, 1990)”, until packaged into the acidic
azurophilic granules of neutrophils that protect the cytoplasmic proteins from these
destructive proteases. Pichia pastoris has been used in this laboratory as a useful host
for the expression of the recombinant mast cell serine proteases tryptase (Niles et al.
1998) and chymase (Lockhart et al. 2005). Consequently, the Pichia pastoris system
was chosen for the stable expression of active rhCatG, that has previously been
described.
EXPERIMENTAL PROCEDURES
Materials
Substrates Succinyl-Val-Pro-Phe-thiobenzyl ester (Suc-VPF-SBzl) was purchased
from Bachem and Suc-Val-Pro-Lys-SBzl ester (Suc-VPK-SBzl) was synthesized for us
by GenScript. Stock solutions of the substrates of 20mM were prepared in dry isopropyl
alcohol. Octyl glucoside (O-8001) and Bowman-Birk (C7268) were obtained from Sigma
Chemicals. TRIS, glycerol, ammonium sulfate, sodium azide, methanol and sodium
chloride were purchased from Fisher Scientific. PAGEgel Cassette Gel-12 well SDS
gels (12% acrylamide) pre-cast with Bis-Tris buffer were purchased from PAGEgel, Inc.
NuPAGE MOPS buffer (20X), MultiMark® Multi-Colored Standard, Simply Blue™
SafeStain, Magic Marker Western Standards pre-stained protein standards, and Pichia
pastoris EasySelect Pichia Expression Kit were purchased from Invitrogen.
SuperSignal™ Chemiluminescent Substrate horseradish peroxidase enhancer and
ImmunoPure® Antibody Anti-goat, rabbit Horseradish Peroxidase, GelCode Blue Stain
were purchased from Pierce. PfuUltra™ Hotstart High-Fidelity DNA Polymerase was
obtained from Stratagene. Rabbit Anti-CatG human IgG (Fab specific) was purchased
from Calbiochem. Yeast Nitrogen Base with ammonium sulfate but without amino acids
was purchased from Research Products International Corporation.

DeepVent DNA

polymerase was obtained from New England Biolabs. Western Blue™, XbaI, BstXI,
and XhoI were purchased from Promega. Competent JM109 E. coli cells were produced
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by a modification of the method of Inoue et al (1990) (Detailed protocol in Appendix).
Micro-titer 96-well half-diameter plates (Product Number 3695) were obtained from
Corning. Recombinant Eglin C was kindly provided by Dr H. P. Schnebi (formerly of
Ciba-Geigy, Basel, Switzerland). The CatG-cDNA in the pUC-9 vector was provided by
Dr. Guy Salvesen (Burnham Institute, San Diego, CA). Native human CatG was
isolated from neutrophils in the laboratory following the method of Martodam et al.
(1979) and the Trasylol affinity chromatography step was repeated.
Methods
A 10X Yeast Nitrogen Base (YNB) solution was prepared by dissolving 67 g of
Yeast Nitrogen Base with ammonium sulfate (but without amino acids) in 1 L of
deionized water followed by filter sterilization. A 500X Biotin solution was prepared by
dissolving 20 mg in 100 ml of deionized water followed by filter sterilization. The Trace
Metals Solution contained 6 g CuSO4·5H2O, 0.08 g NaI, 3 g MnSO4·H2O, 0.5 g CoCl2,
20 g ZnCl2, 0.02 g H3BO3, Na2MoO4·2H2O, FeSO4·7H2O, 4 ml of 6 N H2SO4,and 0.2 g
Biotin per liter that was filter sterilized. A vitamin mix was prepared by dissolving 20 g
casamino acids, 1 g sodium glutamate, 1 g/ L tryptophan, 100 mg dextran sulfate, 400
mg histidine, 40 mg EDTA in 100 ml of water followed by filter sterilization. Pichia
pastoris strain SMD1163 that was considered to be deficient in yeast proteases A and B
and a histidine requiring strain was generously provided by Invitrogen. Basic growth
media was prepared by combining 100 mLof 20% glucose, 100 mL of 100% glycerol,
776 mL of 1X YNB with ammonium sulfate, 12 ml/L Trace Metals Solution, 12 ml/L
Vitamin Solution, 40 µg of histidine, 1 µg/mL of dextran sulfate, 25 µg/mL of ampicillin,
and 100 µg/ml zeocin in a final volume of 1 L. Expression Induction Media contained
0.05% methanol in place of glucose and glycerol. Agar Yeast Extract Peptone Dextrose
Medium plates with Zeocin (YPDS) contained 90 mL deionized water, 2 g peptone, 1 g
yeast extract, 10 mL of 20% dextrose, 2 g agar and 100 µg/ml Zeocin YPDS (yeast
extract peptone dextrose medium with sorbitol) plates contained 1% yeast extract, 2%
peptone, 2% dextrose (glucose), 1 M sorbitol, 2% agar plates, and 100 µg/ml Zeocin.
Construction of pPICza-rhCatG
The full-length cathepsin G cDNA in pUC9 vector was propagated by transformation
into E. coli JM-109 cells and purified using a Qiagen MIDI-Prep. The CatG cDNA was
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then amplified by PCR to add a XhoI site and a KEX2 protease cleavage site at the Nterminus using the primer 5’ TCT CTC GAG AAA AGA ATC ATC GGA GGC CGG GAG
AGC AGG 3’ as shown in Figure 14.
ß----pPICZa----à
TCT CTC GAG AAA AGA
^ XHO I Lys Arg ^Kex

<----Cathepsin G sequence ----à
ATC ATC GGA GGC CGG GAG AGC AGG

2
cleavage

Figure 14 N terminus primer for CatG immature and Mature Forms.
CatG was ligated into the pPICZa vector. Row 1 contains the regions of
the vector and CatG’s sequences. Row 2 has the DNA sequences of
pPICZa and CatG. Row 3 shows the XHOI restriction site, the amino acid
sequences, and the KEX2 cleavage site designating the area of the protein
to be cleaved upon secretion from the cell.
The reverse primer used to generate immature (iCatG; full-length) with a full-length
C-terminus had the sequence 5’ CAA ATT TCT AGA TTA CAG TGG AGT TTC CAT
CTG ATC CAG 3’ (Figure 15). Mature (mCatG) missing the C-terminal 11 amino acids,
but having a C-terminal His Tag sequence to assist in purification, was bioengineered
as shown in Figure 3 with the primer sequence 5’ CTA CTA TCT AGA TTA CTA ATG
ATG ATG ATG ATG ATG GCT TCT CAT TGT TGT CCT TAT CCA 3’ (Figure 16).

<------Cathepsin G sequence
L
D
Q
M
E
T
P
5’ CTG GAT CAG ATG GAG ACC CCC
5’ CTG GAT CAG ATG GAA ACT CCA
3’ GAC CTA GTC TAC CTT TGA GGT

------à ßXbaI cleavage-à
L STOP S
R
N
L
CTG TAA TCT AGA AAT TTG 3’
CTG TAA TCT AGA AAT TTG 3’
GAC ATT AGA TCT TTA AAC 5’

Figure 15 C terminus primer for CatG immature form. CatG and XbaI
cleavage site sections are listed in Row 1. Row 2 has the amino acid
residues of CatG and XbaI. The Corresponding 5’ to 3’ DNA sequences
are grouped into codons in Row 3. Row 4 contains modified DNA
sequences for primer optimization. Row 5 contains the complimentary
strand. iCatG sequence is thought to end in METPL but has a 13 amino
acid extension than the mature form. Blue letters denote bioengineering
sites to improve PCR.

48

Figure 16 C terminus primer for CatG mature form. Sequence ends in TTMRS
and is 13 amino acids shorter than the immature form. This sequence includes 6
histidine residues, 2 stop codons, and an XbaI site for cleavage. CatG, 6X
Histidine, and XbaI cleavage site sections are listed in Row 1. Row 2 has the
amino acid residues of CatG, Histidine, and XbaI. The Corresponding 5’ to 3’
DNA sequences are grouped into codons in Row 3. Row 4 contains the
complimentary strand. mCatG sequence is thought to end in TTMRS.
PCR of the ligated pPICzα-CatG sequence was completed with denaturing at 94º C for
15 seconds, extension at 68º C for 60 seconds and 55º C for 30 seconds. Both Cterminal primers included XbaI restriction sites for cloning into pPICza, with Vector NTI
(Invitrogen) used to design the primers. This design placed a Kex2 protease cleavage
site that was cleaved by the yeast Kex2 protease to remove the yeast alpha mating
factor sequence and generate the N-terminal of active CatG. The PCR product was
analyzed on a 3% Nusieve agarose gel followed by digestion with XhoI and XbaI, gel
purification, and ligation into a previously purified and similarly digested pPICza vector.
Vector NTI was also used to confirm that the XhoI and XbaI restriction digestion sites
did not exist in the center of the rhCatG DNA sequences.
Transformation
The ligated CatG- pPICza vector was transformed into competent JM109 cells with
selection being achieved on low-salt LB plates with Zeocin (25 µg/ml). DNA plasmid
mini-preps for zeocin resistant colonies of both iCatG and mCatG were digested with
XhoI and XbaI and then analyzed on a 1% agarose gels to confirm they contained the
750 base CatG insert. In addition, positive samples were sequenced with the 5’ alpha
factor and 3’ AOX1 specific primers (Invitrogen) to confirm the sequence was in-frame
with the alpha factor initiation codon. Both iCatG- pPICza and mCatG- pPICza vectors
were linearized with BstXI for homologous recombination into the protease deficient
SMD1163 strain of Pichia pastoris that had been made electro competent (Lin49

Cereghino et al. 2005). The 50 µg of cells were transformed with 3 µg of DNA in an
Electro Cell Manipulator 600 (BTX Electroporation System, San Diego, California,
92121) at 21.5 kV (2 mm gap) for 9 milliseconds in a total volume of 50 µL. A volume of
1 mL of cold 1 M sorbitol was added to the cuvette, followed by transfer of the cells to a
sterile 15 mL tube. The tube was incubated at 30°C for 2 hours with shaking and 50100 µL of cells were spread on YPDS plates with Zeocin (100 µg/mL) and incubated at
30°C. Seven iCatG (designated 1-7) and two mCatG positive colonies (designated A
and B) were selected and confirmed through PCR using the 5’ and 3’ AOX1 primers,
based on the criterion that PCR products from non-transformed cells yield a single band
(2200 bp) whereas transformed samples yield an additional band at 1200 base pair
(588 bp plus the expected size the CatG insert- 700 bp). The presence of CatG DNA
was confirmed to be incorporated into the Pichia genome through sequencing at the
Molecular Biology Core Facility (ETSU).

1

2

3

4

5

6

2200 bp
1300 bp

588 bp

Figure 17 Analysis of Pichia Genomic DNA by PCR.
PCR was used to amplify the CatG sequences in the
Pichia genomic DNA resulting from homologous
recombination. Lane 1, 100bp DNA Standard; Lane 2,
SMD1163 control that had not been transformed with
pPICZa (negative control); Lane 3, Pichia strain X-33
transformed with pPICZa chymase (positive control);
Lane 4, pPICZa CatG in X33 insert; Lane 5, Pichia
strain SMD1163 transformed with pPICZa CatG ; Lane
6, Pichia strain X-33 pPICZa.
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Genomic DNA PCR and Sequencing
Confirmation of homologous recombination of CatG DNA sequences into Pichia
pastoris was performed by isolating genomic DNA samples from iCatG and mCatG
colonies followed by PCR with 3’ and 5’AOX1 primers (Invitrogen). Polymerase Chain
Reaction had a denaturing of 94º C for 15 seconds, an extension of 68º C for 1 minute
per kb, and an annealing of 60 º C for 30 seconds, with samples analyzed on a 1%
agarose gel ran for 1 hour at 150 volts followed by ethidium bromide staining (See
Figure 17). Duplicate sample combined with orange loading dye were loaded onto a
3% (Nuseive) gel that was run for 70 minutes at 150 mvolts. The gel was stained for 10
minutes in dilute (1:20,000) cybergreen and excised from the gel and sent to the ETSU
Core Facility who confirmed of the integration of the sequences.

Expression and Growth
Enzyme expression was examined by growth of positive colonies and a nontransformed negative control in 250 mL baffled flasks containing 50 mL of Basic Growth
Media overnight at 30 oC with agitation of 250 RPM. After 24 hours, samples were
switched to Expression Induction Media by the daily addition of 0.5% of methanol and
10 µL /mL histidine (2 gm /100 mL). Enzymatic activity of the protease in the media was
analyzed by removing 2 ml aliquots daily followed by centrifugation at 3000 x g for 5
minutes to yield cell-free media that was then assayed using 50 µM Suc-VPF-SBzl as
substrate.

In Vitro Enzymatic and Protein Assays
CatG activity was measured using either Suc-VPF-SBzl or Suc-VPK-SBzl in assay
buffer comprised of 0.1 M Hepes, 1 M NaCl, 10% glycerol, 0.1 mg/mL heparin, 0.02%
sodium azide, pH 7.5 at a final substrate concentration of 0.5 mM and 4mM
dithiodinitrobenzoic acid (DTNB). The DTNB reacts with the thiobenzene product to
form thiodinitrobenzoic acid that has a 405nm extinction coefficient of 13,000 M-1
(Johnson, 2006). Kinetic assays were performed with 25 µL of sample and reactions
were started by adding 25 µL of 1 mM substrate in assay buffer for a total volume of 50
µL in Corning 96-well microtiter plates, that were monitored at 405nm at room
temperature on a BIO-TEK Instruments EL 312e with KC Junior software. Kinetic data
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were collected by taking readings every 10 seconds over 10 minutes and linear
regression rate curves had a r2 of not less than 0.99. A unit of enzyme activity was
defined as an increase of 1 absorbance unit at 405 nm per minute at room temperature.
Enzyme kinetic analysis were performed on the full length immature CatG to determine
the Vmax (maximum reaction velocity), and Km used the substrate Suc-VPF-SBzl under
the previously mentioned reagents and conditions. The substrate concentration ranged
from 0.07 – 0.99 mM in assay buffer with 0.05 µL of iCatG added to each well for a total
of 150 µL per well. Velocity/Reaction rate (V) data were plotted against the substrate
concentrations (S) and analyzed by non-linear regression with fitting to a hyperbolic
curve using Hyper32 by J.S. Easterby (University of Liverpool), resulting in an r2 of 0.99
and Lineweaver-Burk and Eadie-Hofstee Plots

Kinetic Assay iCatG with VPF Substrate
70
2

R = 0.9688

Activity (mA405/Min)

60
50
40

Lineweaver-Burk Plot Results
0.5 Vmax = 21.13;
Km = 0.1269 mM

30
20
10
0

0.00

0.10

0.20

0.30

0.40

0.50
0.60
0.70
mM of substrate (VPF)

0.80

0.90

1.00

1.10

Figure 18 Km Determination of iCatG with the Suc-VPF-SBzl
substrate. The activity (mA405/minute) was plotted against the
concentration (mM) of Substrate. Concentration of substrate was
increased, providing a linear response (R2 = 0.9688) to determine
Vmax and Km using the chymotrypsin-like substrate.

were used to calculate Vmax and Km (See Figure 18). Protein molecular weights were
calculated from their amino acid sequences using the ProtParam softaware tools on the
ExPASy.org web site (Gill and von Hippel, 1989; Pace et al. 1995). Literature showed
that nCatG has a Km of 0.019 mM and a Kcat of 22, while these experiments produced
a Km of 0.1296. A Kcat value could not be calculated due to incomplete purification.
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Purification
Following a 4-day methanol induction period, the 50 mL of media containing the
mCatG Colonies (A and B) and iCatG Colonies (2 and 4) was centrifuged at 21,000 x g
for 30 minutes. The clear supernatant samples were made 0.25 M NaCl, pH 8.8
followed by storage at 4º C. Samples were concentrated on a Pall Omega 10,000 MW
cut-off membrane in an Amicon stirred cell to a volume of approximately 15 mL, after 3
15 mL washings with 0.25 M MgCl2, that has been reported to stabilize nCatG activity
(Salvesen, 2004). Samples were further concentrated to 5 mL using a 10,000 MW cutoff Macrosep (Pall Corporation) filter by centrifugation at 3000 x g, followed by
concentration on a Nanosep 10K Omega column (Pall Corporation) to approximately
500 µL. The samples were analyzed on an SDS-Page gel, as seen in Figure 19.
Electrophoretic and Mass Spectral Analysis
Protein samples of approximately equal concentrations based on activity, were desalted and dissolved in NuPage LDS Sample Buffer (Invitrogen) with 50 mM
1

2

3

4

5

6

Neg Con.
Colonies
30,000 MW

2

4

Colonies
A

B

20,000 MW
iCatG

mCatG

W/O His tag

With His tag

Figure 19 Qualification of iCatG and mCatG
by size and purity by SDS Page Gel. Samples
were found to be approximately 25,000 daltons.
Lane 1,SeeBlue Plus2 SDS-PAGE standard;
Lane 2, Negative Control; Lane 3, iCatG Colony
2; Lane 4, iCatG Colony 4; Lane 5, mCatG
Colony A; Lane 6, mCatG Colony B.
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dithiothreitol. Samples were analyzed on NuPAGE 12% Bis-Tris pre-cast gels (1.0 mm
X 10 well) using NuPAGE MOPS buffer, with electrophoresis at 200 mvolts for 45
minutes, followed by staining with GelCode Blue (Pierce) Coomassie stain. Protein
imaging and densitometry were accomplished with an Alpha Innotech Imager and
software (See Figure 19). The major band of approximately 26kDa in lane 4 (Colony 4,
iCatG) was excised from the gel and submitted to Columbia University for sequence
confirmation by MALDI-TOF Peptide Mass Fingerprinting (See Figure 20). Theoretical
peaks and actual peak results were determined with the results being placed in Table 7.

31
30
938.39

29
28

RQICVGDRR 1159

LLDQMETPL 1059

27
26

1159.01

25

IFGSYDPRR 1111

24
23
22

RQICVGDR 1004

1059.28

21
% Intensity

20 909.79
19
18
17
16
15
14
13
12
11

VQRDRQCLR 1174
1111.72
1004.52
917.28
1109.15
1154.23
1341.52
1071.951174.91
1021.99
966.99
1080.73
967.94
1213.05
TIQNDIMLLQLSR 1542
1241.35
1252.16
1055.01
1182.66
1347.93
1320.70
1245.86
1434.66
1830.52
1542.75
1328.77
1377.59
1359.21

10
9

1568.66
1643.83
1726.22
1710.53

8
7

1894.47
1948.83
1951.06
2001.01

6
5
4
3
2
1
0
900

1420

1940

Figure 20 MALDI-TOF Peptide Mass
Fingerprinting of iCatG. CatG fragments are
analyzed and depicted on chromatograph after
trypsin digestion. Actual mass of the fragment is
depicted in black, while theoretical sizes are
shown in blue.
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It should be noted that the peptide with a mass of 1059 corresponds with the sequence
LLDQMETPL (See Figure 20), that was consistent to the C terminus of iCatG. Other
identified peptide masses were 1159 (RQICVGDRR), 1111 (IFGSYDPRR), 1004
(RQICVGDR), 1174 (VQRDRQCLR), AND 1542 (TIQNDIMLLQLSR) (See Figure 20
and Table 5).

MALDI-TOF Mass Fingerprinting Results Analyzed with Peptidemass
Peak
No.

Peak
Intensity

Residue
Numbers

Segment of Sequence

Experimental
Experimental
Peak
PeakMass
MW (Da)
(Da)

Theoretical
Theoretical
Peak Mass
(Da)
Peak
MW (Da)

1

31663.47

163-170 /
164-171

RQICVGDR / QICVGDRR

1004.52

1003.51

2

29859.97

227-235

LLDQMETPL

1059.28

1059.54

3

31001.19

155-163

IFGSYDPRR

1111.72

1110.57

4

74274.82

163-171

RQICVGDRR

1159.01

1159.61

5

22961.19

146-154

VQRDRQCLR

1174.91

1173.63

6

21041.41

84-96

asparigine

1542.75

1544.85

7

7953.84

149-162

DRQCLRIFGSYDPR

1726.22

1725.85

8

11766.33

179-199

GDSGGPLLCNNVAHGIVSYG K

2059.36

2058.01

9

11808.8

36-61

EDFVLTAAHCWGSNINVTLG AHNIQR

3302.54

3301.68

TIQNDIMLLQLSR *Potential deamidation on

Table 5 MALDI-TOF Peptide Mass Fingerprinting of iCatG.
Column 1, depicts each of the 10 peaks, with peak 1 having 2
possible segments. Column 2, provides peak intensity of fragments.
Column 3, is the corresponding residues. Column 4, depicts the
residues of the segment of the sequence. Columns 5 and 6, shows
the experimental and theoretical sizes of the segments.

Inhibition Studies
Inhibition studies were conducted on iCatG and mCatG preparations for comparison
with nCatG using 0.5 mM Suc-VPF-SBzl and Suc-VPK-SBzl substrates using the
inhibitors Eglin C (0.00195 nmol/µL for the chymotrypsin-like substrate; 0.00002
nmol/µL for the trypsin-like substrate), TPCK (7.50 mmol/µL), TLCK (2.50 mmol/µL),
and Bowman-Birk, a soybean trypsin and chymotrypsin inhibitor (Birk, 1985) (0.13
nmol/µL for the chymotrypsin-like substrate; 1.27 nmol/µL for the trypsin-like substrate)
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were used. For comparison, the activities of iCatG and mCatG preparations were
diluted with assay buffer to match the activity of 0.22 pmol of nCatG so that 10 µL of the
diluted enzymes could be used in each inhibition assay. The iCatG preparation was
diluted 50 µL into 500 µL and mCatG was diluted 75 uL into 525 µL. Each micro plate
well received 10 µL of each enzyme, followed by 0-50 µL of inhibitor in assay buffer was
added. The total volume of the well was adjusted to 60 µL with assay buffer then
mixed. Incubation of inhibitor for 20 minutes was allowed for binding with the enzyme,
followed by an assay of activity through addition of 50 µL of 1mM substrate in assay
buffer. Plates were shaken at high speed for 10 seconds to mix the reagents prior to
the first read and were then read every 10 seconds for a total of 10 minutes. The initial
velocities of the reactions were determined by linear regression resulting in correlation
coefficients of 0.9 of greater. Each of the 3 forms of CatG were assayed for activity with
the 4 previously mentioned inhibitors, using both the chymotrypsin and trypsin
substrates for a total of 24 inhibition assays and 12 control assays without inhibitor (See
Figures 21, 22, 23, 24).
The IC50 data were calculated by graphing initial velocity of each assay (mA405/min)
on the y-axis versus inhibitor concentration on the X-axis using Microsoft Excel. These

Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and mCatG) by TPCK (MW 351), a
chymotrypsin inhibitor using Suc-V-P-F-SBzl Substrates
R2 value
Avg Units of Activity
Quantity of
CatG
C
of data
CatG
IC50
Lost / Quantity of
Inhibitor for
type
terminal
points
Concentration (mMol)
Inhibitor
total inhibition
nCatG
Colony B
Colony 2

Max slope
0.26 lost/mmol

375 mmoles

0.8800

20 uL> 200 uL;
10 uL > 1000 uL

225

with 6 His
Max slope
Tag
0.24 lost/mmol

330 mmoles

0.9651

50 uL> 500 uL;

146

225 mmoles

0.9693

75 uL> 525 uL

111

none

with 13
aa tail

Max slope
0.55 lost/mmol

Table 6 Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and
mCatG) by TPCK (MW 351), a chymotrypsin inhibitor using Suc-VPF-SBzl
Substrate. This table summarizing the results from the inhibition analysis with
Column 1 depicting the type of CatG used, column 2 showing the type of C
terminus associated with each enzyme, column 3 shows the activity lost per
inhibitor. Column 4 shows the quantity needed for total inhibition, column 5
shows the R2 value, column 6 shows the concentration of the enzyme, and
column 7 depicts the IC50 values for each reaction.
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plots had correlation coefficients as follows: nCatG (0.88-0.98), iCatG (0.93-0.99), and
mCatG (0.77-0.98). The “Quantity of Inhibitor for 50% inhibition” (IC50) was extrapolated
from these graphs and plotted as bar graphs (Figures 25, 26, 27, & 28) and recorded in
table form along with the “Average Units of Activity Lost per Quantity of Inhibitor” and r2
values (See Tables 6, 7, 8, 9).

Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and mCatG) by TPCK (MW 351), a
chymotrypsin inhibitor using Suc-V-P-K-SBzl Substrates
R2 value
Avg Units of Activity
Quantity of
CatG
C
of data
CatG
IC50
Lost / Quantity of
Inhibitor for
type
terminal
points
Concentration (mMol)
Inhibitor
total inhibition
nCatG
Colony B
Colony 2

Max slope
0.30 lost/mmol

300 mmoles

0.9241

20 uL> 200 uL;
10 uL > 1000 uL

125

with 6 His
Max slope
Tag
0.14 lost/mmol

270 mmoles

0.9487

50 uL> 500 uL;

114

205 mmoles

0.9188

75 uL> 525 uL

90

none

with 13
aa tail

Max slope
0.25 lost/mmol

Table 7 Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and
mCatG) by TPCK (MW 351), a chymotrypsin inhibitor using Suc-VPK-SBzl
Substrate. This table summarizing the results from the inhibition analysis with
Column 1 depicting the type of CatG used, column 2 showing the type of C
terminus associated with each enzyme, column 3 shows the activity lost per
iInhibitor. Column 4 shows the quantity needed for total inhibition, column 5
shows the R2 value, Column 6 shows the concentration of the Enzyme, and
column 7 depicts the IC50 values for each reaction.
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Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and mCatG) by Eglin C (MW 5185), a
chymotrypsin inhibitor using Suc-V-P-F-SBzl Substrates
R2 value
Avg Units of Activity
Quantity of
CatG
C
of data
CatG
IC50
Lost / Quantity of
Inhibitor for
type
terminal
points
Concentration
(pMol)
Inhibitor
total inhibition
Max slope
116.9 lost/picomol

0.713 Picomols

0.9472

20 uL> 200 uL;
10 uL > 1000 uL

0.3

with 6 His
Max slope
Tag
0.823 lost/picomol

84 Picomols

0.9644

50 uL> 500 uL;

42

164 Picomols

0.9423

75 uL> 525 uL

72

none

nCatG
Colony B
Colony 2

with 13
aa tail

Max slope
0.762 lost/picomol

Table 8 Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and
mCatG) by Eglin C (MW 5158), a chymotrypsin inhibitor using Suc-VPFSBzl Substrate. This table summarizing the results from the inhibition analysis
with Column 1 depicting the type of CatG used, volumn 2 showing the type of C
terminus associated with each enzyme, volumn 3 shows the sctivity lost per
iInhibitor. Column 4 shows the quantity needed for total inhibition, column 5
shows the R2 value, column 6 shows the concentration of the enzyme, and
column 7 depicts the IC50 values for each reaction.

Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and mCatG) by Eglin C (MW 5185), a
chymotrypsin inhibitor using Suc-V-P-K-SBzl Substrates
R2 value
Avg Units of Activity
Quantity of
CatG
C
of data
CatG
IC50
Lost / Quantity of
Inhibitor for
type
terminal
points
Concentration
(pMol)
Inhibitor
total inhibition
nCatG
Colony B
Colony 2

Max slope
246.2 lost/picomol

0.325 Picomols

0.9560

20 uL> 200 uL;
10 uL > 1000 uL

0.153

with 6 His
Max slope
Tag
0.442 lost/picomol

73 Picomols

0.9513

50 uL> 500 uL;

35

77 Picomols

0.9523

75 uL> 525 uL

36.3

none

with 13
aa tail

Max slope
0.399 lost/picomol

Table 9 Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and
mCatG) by Eglin C (MW 5158), a chymotrypsin inhibitor using Suc-VPKSBzl Substrate. This table summarizing the results from the inhibition analysis
with Column 1 depicting the type of CatG used, column 2 showing the type of C
terminus associated with each enzyme, column 3 shows the activity lost per
inhibitor. Column 4 shows the quantity needed for total inhibition, column 5
shows the R2 value, column 6 shows the concentration of the enzyme, and
column 7 depicts the IC50 values for each reaction.
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Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and mCatG) by Bowman-Birk (MW
7873), a dual inhibitor using Suc-V-P-F-SBzl Substrates
R2 value
Avg Units of Activity
Quantity of
CatG
C
of data
CatG
IC50
Lost / Quantity of
Inhibitor for
type
terminal
points
Concentration (nMol)
Inhibitor
total inhibition
nCatG
Colony B
Colony 2

Max slope
10.34 lost/nanomol

10 nM

0.9786

20 uL> 200 uL;
10 uL > 1000 uL

4.7

with 6 His
Max slope
Tag
4.692 lost/nanomol

16 nM

0.957

50 uL> 500 uL;

7.6

11 nM

0.982

75 uL> 525 uL

5.25

none

with 13
aa tail

Max slope
7.991 lost/nanomol

Table 10 Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and
mCatG) by Bowman-Birk (MW 7873), a dual inhibitor using Suc-VPF-SBzl
Substrate. This table summarizing the results from the inhibition analysis with
Column 1 depicting the type of CatG used, column 2 showing the type of C
terminus associated with each enzyme, column 3 shows the activity lost per
inhibitor. Column 4 shows the quantity needed for total inhibition, column 5
shows the R2 value, column 6 shows the concentration of the enzyme, and
column 7 depicts the IC50 values for each reaction.

Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and mCatG) by Bowman-Birk (MW
7873), a dual inhibitor using Suc-V-P-K-SBzl Substrates
R2 value
Avg Units of Activity
Quantity of
CatG
C
of data
CatG
IC50
Lost / Quantity of
Inhibitor for
type
terminal
points
Concentration
(pMol)
Inhibitor
total inhibition
nCatG

none

Colony B

with 6 His
Tag

Colony 2

with 13
aa tail

Max slope
78.93 lost/picomol

1.45 pM

0.9233

20 uL> 200 uL;
10 uL > 1000 uL

0.57

Max slope
0.64 lost/nanomol

41 nM

0.9302

50 uL> 500 uL;

21,000

Max slope
1.485 lost/nanomol

37 nM

0.7659

75 uL> 525 uL

13,800

Table 11 Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and
mCatG) by Bowman-Birk (MW 7873), a dual inhibitor using Suc-VPK-SBzl
Substrate. This table summarizing the results from the inhibition analysis with
Column 1 depicting the type of CatG used, column 2 showing the type of C
terminus associated with each enzyme, column 3 shows the activity lost per
iInhibitor. Column 4 shows the quantity needed for total inhibition, column 5
shows the R2 value, column 6 shows the concentration of the enzyme, and
column 7 depicts the IC50 values for each reaction.
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Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and mCatG) by TLCK (MW 369), a
trypsin inhibitor using Suc-V-P-F-SBzl Substrate.
R2 value
Avg Units of Activity
Quantity of
CatG
C
of data
CatG
IC50
Lost / Quantity of
Inhibitor for
type
terminal
points
Concentration (mMol)
Inhibitor
total inhibition
nCatG

none

Max slope
0.31 lost/mmol

275 mM

0.9374

20 uL> 200 uL;
10 uL > 1000 uL

145

Colony B

with 6 His
Tag

Max slope
0.48 lost/mmol

212 mM

0.9315

50 uL> 500 uL;

100

Colony 2

with 13
aa tail

Max slope
0.30 lost/mmol

240 mM

0.9284

75 uL> 525 uL

111

Table 12 Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and
mCatG) by TLCK (MW 369), a trypsin inhibitor using Suc-VPF-SBzl
Substrate. This table summarizing the results from the inhibition analysis with
Column 1 depicting the type of CatG used, column 2 showing the type of C
terminus associated with each enzyme, column 3 shows the activity lost per
inhibitor. Column 4 shows the quantity needed for total inhibition, column 5
shows the R2 value, column 6 shows the concentration of the enzyme, and
column 7 depicts the IC50 values for each reaction.

Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and mCatG) by TLCK (MW 369), a
trypsin inhibitor using Suc-V-P-K-SBzl Substrate.
Avg Units of Activity
Quantity of
Lost / Quantity of
Inhibitor for
Inhibitor
total inhibition

R2 value
of data
points

CatG
type

C
terminal

CatG
IC50
Concentration (mMol)

nCatG

none

Max slope
0.36 lost/mmol

750 mM

0.9666

20 uL> 200 uL;
10 uL > 1000 uL

121

Colony B

with 6 His
Tag

Max slope
0.28 lost/mmol

170 mM

0.9933

50 uL> 500 uL;

86

Colony 2

with 13
aa tail

Max slope
0.29 lost/mmol

115 mM

0.8947

75 uL> 525 uL
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Table 13 Inhibition of 50% Activity of CatG Enzymes (nCatG, iCatG and
mCatG) by TLCK (MW 369), a trypsin inhibitor using Suc-VPK-SBzl
Substrate. This table summarizing the results from the inhibition analysis with
Column 1 depicting the type of CatG used, column 2 showing the type of C
terminus associated with each enzyme, column 3 shows the activity lost per
inhibitor. Column 4 shows the quantity needed for total inhibition, column 5
shows the R2 value, column 6 shows the concentration of the enzyme, and
column 7 depicts the IC50 values for each reaction.
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RESULTS and DISCUSSION
Expression Kinetics
Aliquots of 0.5 mL Pichia pastoris-mCatG media supernatant was obtained
following centrifugation at 21,00xg for 5 minutes were prior to induction and at 24 hours
intervals post-induction. A total of 10 µL of the media containing enzyme was placed in
each well along with 40 µL of assay buffer for a total volume of 50 µL. Colonies A and
B (mCatG) contained activities of 17.9 mA405/minute/10 µL and 18.9 mA405/minute/10
µL, respectively. Colonies 1-4 (iCatG ) contained activities of 18.0, 16.4, 14.9, and 16.4
mA405/minute/10 µL, respectively). The activity from Colonies B and 2 were used to
calculate the total units (mA045) for the 50 mL samples, with Colony B having a total
activity of 94,500 mA405 and Colony 2 having a total activity of 82,000 mA405 (See
Table 10).

Activity of M edia Prior to Purification
Colony B
10
50
5
18.9
94.5
1.89
50,000
94,500

Sample
Volume of enz yme
Total volume in w ell
Dilution
activity / 10 uL
activity / 50 uL
activity / 1 uL
Total Volume (uL)
Total Units (mA405)

Colony 2
10
50
5
16.4
82
1.64
50,000
82,000

Table 14 Activity of Colony B and Colony 2 in the Media After 24
Hours. A table summarizing the Activity of each of the 2 Samples, the
volume of enzyme, (Row 1) and their total volume in each well (Row 2);
their dilution (Row 3); the activity per Well (Row 4) and their activity per
50 µL (Row 5) and their Activity per 1 µL (Row 6); the total volume of
enzyme Media (Row 7); and Total Activity Units for the Entire Volume
(Row 8).

The negative control of untransformed cells was found to contain only one-third of
the activity (5.8 mA405/minute/10 µL) when compared to the transformed samples.
Although all iCatG (1-4) and mCatG (A, B) colonies cleaved the substrate at rates
greater than the negative control, Colonies #2, #4 and A, B were selected for
optimization of protein expression and were grown and induced in 200 mL baffled flasks
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containing 50 mL of Yeast Growth Media under the same conditions as previously
stated and were harvested after 4 days for purification. After purification, the 4 active
samples (Colonies 2, 4, A, and B) were analyzed on SDS-PAGE producing a protein
band at approximately 26 kDa corresponding to the theoretical values of both iCatG
(26,758 MW) and mCatG (25,441 MW) (See Figure 19). The results from these two
analyses were consistent with CatG enzymatic activity and expected size.

Purification and Confirmation
A 3-step purification procedure was employed, consisting of a combination of
stirred cells and centrifugation columns, to concentrate the total volume from 50 mL to
0.5 mL. (See Table 11) Although 10,000 K cutoff was used, a larger pore diameter
(20,000 MW) would probably yield a purer product and reduce the overall purification
time.

Purification Step Employed on Cathepsin G

Purification Step
Amicon stirred cell (10K
Cutoff)
10,000 MW cut-off Macrosep
column
10K Nanosep Omega
column

Beginning
Quantity (mL)

Ending Quantity
(mL)

50

15

15

5

5

0.5

Table 15 Purification Steps of CatG Enzymes (nCatG, iCatG
and mCatG). A table summarizing the purification steps
(column 1) and their Beginning and Ending Quantity of Enzyme
(columns 2 and 3). An approximate reduction of over 100 fold
was completed through the 3-stage process with a final volume
of 500 µL.
The purified samples were analyzed on an SDS-Page gel, as seen in (See Figure 19)
with each of the mCatg samples (Colonies A and B) and iCatG (Colonies 2 and 4) being
approximately 26 KDa. Colony B band appearing to be more concentrated as
compared with Colony A and Colonies 2 and 4 being of approximate concentrations.
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Although the samples were not 100% pure, major bands were displayed in the
expected size range of 25-30 kDa and a minor diffuse band in the 50 to 60 kDa range,
that was approximately twice the size of the major bands. Diffuse bands of higher
molecular size were observed with the expression of tryptase (Niles et al. 1998) and
with chymase (Lockhart et al. 2005) when expressed by Pichia pastoris. These larger,
diffuse bands may have resulted from hyper glycosylation (Macauley-Patrick et al.
2005).
A duplicate sample of Colony 4 protein was analyzed on SDS-Page gel and
sequenced by MALDI-TOF Mass Fingerprinting after trypsin fragmentation. The
resulting peptide masses were compared with the masses predicted by PEPTIDE
MASS (ExPASy.org; Wilkins et al. 1997), resulting in 10 fragments, ranging from 8 to 22
residues, and all fragments being within 1 dalton of insilico predicted results. The Cterminal fragment sequence LLDQMETPL, that would be the last nine amino acids
cleaved from the iCatG sequence, matched the predicted mass to within 0.26 daltons.
The molecular weight of the fragments detected ranged from 1004.52 daltons to 3302.5
daltons and the intensity having a low of 7954 with 6 of the 10 fragments having
intensities between 21,000 and 75,000 (See Figure 20 and Table 7).
A percent recovery of enzyme for Colonies 2, 4, A, and B was calculated based
on the A280 of the purified samples and the extinction coefficient obtained from the
Quantification of Enzyme After Purification
A280/ Ex.
Coefficient Final Purified
(mg/mL)
Volume (mL)

Total
Protein
(mg)

% of Total
Initial
Protein of
Total
Volume of
gel
CatG (mg) Media (mL)

mg of
Protein /L
of Media

Colony
(Form)

A280

Extinction
Coefficient

A
(Mature)

0.825

0.952

0.87

0.5

0.43

55.3

0.240

50

4.79

B
(Mature)

1.332

0.952

1.40

0.5

0.70

68.0

0.476

50

9.51

2
(Immature)

1.561

0.891

1.75

0.5

0.88

59.1

0.518

50

10.35

4
(Immature)

1.704

0.891

1.91

0.5

0.96

60.8

0.581

50

11.63

Table 16 Quantification of Enzyme After Purification. A table summarizing
each enzyme (mature/immature) and Colony along with its A280 and extinction
coefficient (columns 2 and 3) that are used to calculate its concentration (column
4), the final purified volume of enzyme (column 5), and quantity of total protein
(column 6). The percentage of enzyme of each gel band (column 7), the quantity
of CatG (column 8), the initial volume of media (column 8) and the quantity of
CatG produced per liter of media (column 9) are also displayed.
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Expasy website. The concentration of total protein was calculated and the percent
purity was determined from the SDS page gel (See Figure 19) using Adobe Photoshop.
The total quantity of CatG was then calculated and ranged between 0.24 mg (Colony A)
and 0.58 mg (Colony 4). The final volume of purified enzyme was 0.5 mL, reduced from
the initial volume of 50 mL of media. After purification, a quantity of enzyme per liter
was calculated and found to range of between 4.79 mg/ L (Colony A) and 11.63 mg/ L
(Colony 4) (See Table 12).

Kinetic Comparison of iCatG with nCatG
The Km of iCatG with the substrate Suc-VPF-SBzl was determined for comparison
with the published Km of nCatG with this substrate. The iCatG preparation was diluted
1:2 with water and 1 µ L of enzyme was used in each micro plate well. The substrate
concentration was varied from 0 to 0.99 mM in a total assay volume of 150 µL. Initial
rates varied from 0.149 to 58.7 mA405/minute. Analysis of the rate data (J.S. Easterby
University of Liverpool, Lineweaver-Burk and Eadie-Hofstee Plots) yielded a Km of 0.13
mM (Figure 18), that was approximately 7 times higher than the published Km of 0.019
mM with nCatG (Powers et al. 1989). This experiment, along with the other activity
kinetics that were performed, indicated that the extended C-terminus of iCatG increased
the substrate binding. Unfortunately, because the iCatG preparation used was not pure
the kinetics could be influenced by a contaminating enzyme.

Inhibition Analysis
In order to compare iCatG and mCatG with nCatG, and with each other, inhibition
assays were performed using two chloromethyl ketone inhibitors that function as
irreversible inhibitors via reaction with the active site histidine of serine (Schoellmann
and Shaw, 1963) and cysteine (Walker et al. 1994) proteases. TLCK and TPCK
preferentially inhibit trypsin-like and chymotrypsin-like proteases, respectively (Shaw,
1975). In addition to the chloromethylketone inhibitors, two small naturally occurring
proteins that inhibit nCatG were examined for inhibition of iCatG and mCatG. The first
of these was Eglin C a 70 amino acid protein derived from the leech Hirudo medicinalis
(Schnebli et al. 1985) that inhibits neutrophil elastase and CatG (Braun et al. 1987).
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The second was the Bowman-Birk inhibitor, a small protein with a molecular weight of
7872 that was derived from the soybean (Birk, 1985). Although not shown, all 4
inhibitors totally inhibited all 3 enzymes using both substrates (See Figures 21, 22, 23,
24).

Maximum slope (mA405/min)

Inhibition by EglinC
80
70

nCatG with VPF
substrate
mCatG with VPF
substrate

60
50

iCatG with VPF
substrate

40
30
20

nCatG with VPK
substrate
mCatG with VPK
substrate

10
0
0

25

50

75

100

picomols of Eglin C

iCatG with VPK
substrate

Figure 21 Inhibition of CatG (nCatG, iCatG and mCatG) with
EglinC, a “chymotrypsin-like” inhibitor, using 2 different
substrates (Suc-VPF-SBzl and Suc-VPK-SBzl) to Determine
(IC50). The activity (mA405/minute) was plotted against the
increasing concentration (pM) of Inhibitor. The concentration of
inhibitor producing a 50% reduction of activity was determined
from these data.
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Maximum slope (mA405/min)

Inhibition by Bowman-Birk

90
80
70
60
50
40
30
20
10
0
0

10

20

30

nCatG with VPF
substrate
mCatG with VPF
substrate
iCatG with VPF
substrate
nCatG with VPK
substrate
mCatG with VPK
substrate
iCatG with VPK
substrate

40

nanomols of Bowman-Birk

Figure 22 Inhibition of CatG (nCatG, iCatG and mCatG) with
Bowman-Birk, a both a trypsin and chymotrypsin enzyme
inhibitor, using 2 different substrates (Suc-VPF-SBzl and
Suc-VPK-SBzl) to Determine (IC50). The activity
(mA405/minute) was plotted against the concentration (nM) of
Inhibitor. Concentration of inhibitor was increased, providing a
decrease in activity. The concentration of inhibitor producing a
50% reduction of activity was determined from these data.
Inhibition by TLCK
nCatG with VPF substrate

140

mCatG with VPF substrate

Maximum slope (mA405/min)

120

iCatG with VPF substrate
nCatG with VPK substrate

100

mCatG with VPK substrate

80

iCatG with VPK substrate

60
40
20
0
0

20

40

60

80

100

mMols of TLCK

Figure 23 Inhibition of CatG (nCatG, iCatG and mCatG) with
TLCK, a “trypsin-like” inhibitor, using 2 different substrates
(Suc-VPF-SBzl and Suc-VPK-SBzl) to Determine (IC50). The
activity (mA405/minute) was plotted against the concentration (mM)
of Inhibitor. Concentration of inhibitor was increased, providing a
decrease in activity. The concentration of inhibitor producing a 50%
reduction of activity was determined from these data.
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Inhibition by TPCK

Maximum slope (mA405/min)

nCatG with VPF substrate

140

mCatG with VPF substrate

120

iCatG with VPF substrate

100

mCatG with VPK substrate

nCatG with VPK substrate
iCatG with VPK substrate

80
60
40
20
0
0

20

40

60

80

mMols of TPCK

Figure 24 Inhibition of CatG (nCatG, iCatG and mCatG)
with TPCK, a “chymotrypsin-like” inhibitor, using 2
different substrates (Suc-VPF-SBzl and Suc-VPK-SBzl) to
Determine (IC50). The activity (mA405/minute) was plotted
against the concentration (mM) of Inhibitor. Concentration of
inhibitor was increased, providing a decrease in activity. The
concentration of inhibitor producing a 50% reduction of activity
was determined from these data.
Eglin C concentrations needed for 50% inhibition (IC50) of equal amounts of activity
were more than 100 fold less for nCatG (0.34 pMols) as compared to mCatG (72 pMols)
and iCatG (42 pMols). When inhibition was assayed using the Suc-VPF-SBzl substrate
the IC50s for Eglin C with nCatG (0.15 pMols) were more than 200 fold less than those
of mCatG (36.3 pMols) and iCatG (35 pMols) (See Figure 25).
TPCK, that inhibits “chymotrypsin-like” enzymes, was similarly effective with each
CatG form, resulting in IC50s with nCatG (225 mMols), mCatG (111 mMols), and iCatG
(146 mMols), using the Suc-VPF-SBzl substrate. Interestly, by this measure TPCK was
more effective against mCatG and iCatG than against nCatG. However, when using the
Suc-VPK-SBzl substrate the IC50s were virtually equal; (nCatG, 125 mMols; mCatG, 90
mMols; iCatG, 114 mMols) (See Figure 26). These data show that a chymotrypsin
inhibitor also
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Figure 25 Comparison of IC50 of CatG (nCatG, iCatG and
mCatG) with EglinC, a “chymotrypsin-like” enzyme inhibitor.
The concentration (pM) of Inhibitor resulting in 50% inhibition of
activity, using 2 different substrates (Suc-VPF-SBzl and Suc-VPKSBzl) was compared between enzymes. nCatG is depicted in green
histograms; iCatG is depicted in blue histograms; and mCatG is
depicted in red histograms.
inhibits the trypsin-like activity of all the CatG enzymes, that indicated that the
recombinant enzyme activities were due to CatG rather than a contaminant. The
“trypsin-like” inhibitor, TLCK had an IC50 only slightly higher for nCatG (145 mMols) as
compared to mCatG (111 mMols) and iCatG (100 mMols), using the Suc-VPF-SBzl
substrate. These data showed that a trypsin inhibitor also inhibited the chymotrypsinlike activity of all the CatG enzymes, a further indication that the recombinant enzyme
activities were due to CatG rather than a contaminant. Using the Suc-VPK-SBzl
substrate (nCatG, 121 mMols; mCatG, 54 mMols; iCatG, 86 mMols) (See Figure 27) the
IC50 were again similar.
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IC50 Inhibition of Enzymes by TPCK
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Figure 26 Comparison of IC50 of CatG (nCatG, iCatG and
mCatG) with TPCK, a “chymotrypsin-like” inhibitor. The
concentration (mM) of Inhibitor resulting in 50% inhibition of
activity, using 2 different substrates (Suc-VPF-SBzl and SucVPK-SBzl) was compared between enzymes. nCatG is depicted
in green histograms; iCatG is depicted blue histograms; and
mCatG is depicted in red histograms.

Bowman-Birk, a small compound from Streptomyces hygroscopicus with a molecular
weight of 604, resulted in the greatest variation in IC50s between recombinant enzymes
(nCatG 0.57 pMols; mCatG 13,800 pMols; iCatG 21,000 pMols) using the Suc-VPFSBzl substrate. However, the variances in IC50 values were much less using the SucVPK-SBzl substrate (nCatG, 0.3 pMols; mCatG, 72 pMols; iCatG, 42 pMols) (See
Figure 28). Comparisons between the immature and mature forms of the recombinant
enzymes found iCatG to have an equal or greater IC50 in 6 out of the 8 inhibition
analyses, although more investigation needs to be conducted to determine if there may
be a correlation between the 13 amino acid tail and enhanced inhibition. It should also
be noted that the recombinant enzymes may have larger IC50s than the native forms
due to yeast’s tendency to hyperglycosylate. A second possibility may exist that
dextran sulfate, that was added to help stabilize the recombinant enzyme, was still
associated with the protein that may occlude specificity of the inhibitor. However, this
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IC50 Inhibition of Enzymes by TLCK
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Figure 27 Comparison of IC50 of CatG (nCatG, iCatG
and mCatG) with TLCK, a “chymotrypsin-like” inhibitor.
The concentration (mM) of Inhibitor resulting in 50%
inhibition of activity, using 2 different substrates (Suc-VPFSBzl and Suc-VPK-SBzl) was compared between enzymes.
nCatG is depicted in green histograms; iCatG is depicted
blue histograms; and mCatG is depicted in red histograms.

analysis also helps to verify that the first active recombinant CatG was produced
because the chymotrypsin inhibitor, Bowman-Birk, was able to totally inhibit the activity
on both trypsin-like and chymotrypsin-like substrates. The ability of TLCK (trypsin
inhibitor) to inhibit the “chymotrypsin trypsin-like”activity using the Suc-VPF-SBzl
substrate and both TPCK and Eglin C’s (chymotrypsin inhibitor) ability to inhibit the
“trypsin-like”activity against Suc-VPK-SBzl substrate also substantiated the expression
of an enzyme with dual specificity.
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IC50 Inhibition of Enzymes by Bowman-Birk
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Figure 28 Comparison of IC50 of CatG (nCatG, iCatG and
mCatG) with Bowman-Birk, a dual trypsin and chymotrypsin
enzyme inhibitor. The concentration (pM) of Inhibitor resulting in
50% inhibition of activity, using 2 different substrates (Suc-VPFSBzl and Suc-VPK-SBzl) was compared between enzymes.
nCatG is depicted in green histograms; iCatG is depicted in blue
histograms; and mCatG is depicted in red histograms.
Concluding Remarks
The findings presented were consistent with the Pichia-expressed enzyme activities
being due to recombinant CatG in both its immature and mature forms. This highly toxic
enzyme, normally expressed as a zymogen and then activated upon entering the
azuorphilic granules in neutrophils and cytoplasmic granules in mast cells, has been
expressed by transforming Pichia pastoris. Although insufficient amounts of enzyme
was produced to quantitate final yields, the partial purification protocol consisting of only
centrifugation and size exclusion columns could be modified to further enhance enzyme
yield. Expression of recombinant CatG eliminated the hazards of working with blood
products while providing forms for further investigation may advance understanding of
this important enzyme.
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CHAPTER 4
SUMMARY OF EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN
MAST CELL CHYMASE AND CATHEPSIN G

Discussion
This dissertation reports the expression and characterization of recombinant human
mast cell chymase and recombinant human cathepsin G, that is found in mast cells and
in neutrophils. The expression host for both enzymes was the yeast Pichia pastoris.
The work on recombinant chymase (Chapter 2) has been published in the journal
Biotechnology and Applied Biochemistry (Lockhart et al. 2005). Additionally, this work
was presented at the 2004 ETSU Appalachian Research Forum, winning the first place
Student Choice Award in Division III, and at the 2004 June meeting of the American
Society for Biochemistry and Molecular Biology held in Boston, MA. Chapter 3 has
been written with the expectation that it will be submitted for publication.
Both enzymes were proven to be serine proteases with chymotrypsin-like activities;
however, cathepsin G has been proven to be unique in that it also cleaved trypsin-like
substrates. There were two major advantages in production of these enzymes in the
recombinant form. The first advantage was that the availability of recombinant enzymes
avoided having to purify these enzymes from blood and tissues, that has been shown to
be laborious and potentially a hazardous process. Secondly, site-directed mutagenesis
has been found to be possible with recombinant enzymes, that can now allow possible
experiments to test the importance of single amino acids in CatG’s structure and
function. Pichia pastoris was chosen as the expression host because it worked well for
the expression of human mast cell tryptase (Niles et al. 1998). Additionally, both
chymase and cathepsin G are classified as glycoproteins and Pichia, a yeast, being
eukaryotic, produced post-translational modifications similar though not identical to
mammalian cells. Another advantage of expression of these enzymes in Pichia was the
DNA coding for the recombinant protein was integrated into the host genome, rather
than being in a plasmid vector. Whereas bacterial hosts can lose their plasmids,
transformed Pichia has been shown to be very stable hosts as the genetic information
was actually inserted into the genomic DNA by homologous recombination. The media
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for growth of Pichia has proven to be inexpensive and induction of expression with
methanol did not require any special chemicals or conditions. Finally, the pPICza
vector (Invitrogen) allowed for selection of transformed E. coli and Pichia based on
zeocin resistance.
Chymase
Qualification of the experiments validated recombinant expression of chymase at
larger quantities than previously documented. The expression of rChymase in Pichia
pastoris resulted in secretion of the active enzyme at higher levels than previously
reported and avoided an activation step required by other expression methods. The
Kex2 site of Pichia pastoris expression system was located before the N-terminus of the
chymase enzyme and activated the rChymase by removing the alpha mating factor
fusion used to direct the rChymase for secretion, thus allowing the rChymase to be
excreted from the cell without any additional folding or activation.
Purification of rChymase from the culture media was accomplished by
hydrophobic interaction chromatography on a Tosopearl butyl column followed by
affinity chromatography on Toysopearl AF-heparin. This method yielded at least a 10fold increase of rChymase than previously reported. The purified rChymase was 96%
active based on its reaction with recombinant Eglin C. Changes in media and
fermentation conditions may also be explored to improve expression yields. Chymase
expression levels achieved the highest documented quantities for an active enzyme.
Although other systems had higher expression levels, they were inactive and required
an additional activation step. In addition, with the secreted enzyme, the producing cells
could potentially be used for a longer period of time because purification of enzyme
does not require cell destruction.
The yeast expression system also tended to glycosylate proteins similarly to
mammalian systems, thus producing an enzyme more comparable to the human
protease. However, Pichia also tended to hyperglycosylate proteins, that could be
potentially detrimental depending upon application. Future studies may include
mutating glycosylation sites or using Pichia host strains that have been modified to
glycosylate more like mammalian cells.
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Cathepsin G
Fully active recombinant human chymase was expressed in larger quantity than
had previously been reported in eight publications by other authors. Uniquely, our
bioengineering approach coupled with the Pichia pastoris host resulted in the secretion
of active enzyme, thus avoiding the two laborious tasks of cell lysis and enzyme
activation. Through the previously described efforts, the first active recombinant human
cathepsin G was expressed in both its immature and mature forms. Previous efforts
have been unsuccessful in recombinantly expressing active CatG enzyme that was
probably due to antimicrobial activity of CatG (Bangalore et al. 1990; Miyasaki, 1991;
Shafer et al. 1991) toward the expression host E. coli. An active unregulated CatG
protease released intracellularly could potentially destroy structural proteins and even
the DNA of cells. Bioengineering of the active protease, along with its attachment to the
Kex2 site, was devised to prevent the enzyme from destroying or killing its host. The
alpha secretion factor allowed the active enzyme to be regulated internally then
secreted externally, thus shielding the cellular machinery from the effects of the
protease. However, even the active secreted protein has the ability to externally
destroy some cell lines, but Pichia was not considered to be one apparently due to the
fermentation ability of yeasts. In addition, Pichia was able to grow at an approximate
pH of 5, that was not considered optimal for CatG activity.
Bioengineering of both an immature and mature version of CatG will allow further
research to address the purpose of the C terminal extension and its deletion upon
maturation in the granule. The N terminal deletion of CatG has been resolved, but the
C terminal deletion has not been determined although several theories have been
proposed including attachment, transport, and activation. This research has eliminated
the theory that the C terminal was responsible for activity because both forms of CatG
were active at comparable levels, that leads one to pursue the concepts of transport or
attachment as the most viable options for the extensions. Additional research upon the
immature form of CatG can help to resolve this issue.
Through 3D structural and sequence evaluation, it was also determined that CatG
possesses “arginine-pairing” especially apparent on its outer residues. This novel
design potentially allows ionic interactions to occur with other negatively charged
surfaces or residues. The positively charged outer surface was attracted to negatively
charged cellular glycoproteins and even the phosphate backbone of DNA. However,
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this unique “hyper cationic charge” was also probably detrimental to purification
methods as it could bind to silicates in glass and carboxyl groups of filters. Further work
needs to be conducted on evaluating an uncharged or positively charged surface of
purification products in order to improve expression quantities and yields.
Recombinant production of the serine proteases CatG and chymase reduced the
potential dangers associated with handling of blood products as some methods stipulate
for protein production. In addition, each of these enzymes was secreted in its active
form and does not require any further processing for activity. The potential for the
yeasts to hyperglycosylate the proteins could exist as compared to other expression
systems; although this does not appear to have happened at least to the extent that
activity has been affected.
During expression of both CatG and chymase with the Invitrogen Easy Select
Expression System, we were able to determine that the untransformed cell lines (X33,
SMD1163) provided us excreted small quantities of a protease with chymotrypsin
activity when methanol was added during the induction phase. The enzyme responsible
for this activity was probably associated with the methanol breakdown because the
activity appears during the induction phase. Surprisingly, even the non-transformed
“protease deficient” variant SMD1163 produced activity using the chymotrypsin-like
substrate. However, we were able to use a control to eliminate the “background”
activity with chymase and were able to exploit CatG’s dual specificity by using a trypsin
substrate to overcome this problem. A transformable cell line with the deleted ability to
produce an enzyme with chymotrypsin-like activity would be valuable to protease
expression research.
Media compositions were also evaluated to identify the optimal growth ingredients
while attempting to minimize impurities for enhanced purification. Pichia can be grown
in several different media types but can be very selective as it may not express the
recombinant proteins. Although Invitrogen recommends BMGY/BMMY media that has
been shown to be excellent for cell growth, this media contains quantities of unwanted
impurities that can hinder purification. CatG expression used YNB media,
supplemented with additives (vitamins, trace metals, etc.), appeared to both optimize
growth, with A600s of over 200, and expression while reducing the quantity of
adulterated materials. The YNB media provided all of the necessary nutrients while
simplifying purification.
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Dextran sulfate was added to stabilize the enzyme, although we did not confirm its
effect on expression or purification. An alternative to dextran sulfate such as albumin,
heparin, or even a smaller molecular weight of dextran sulfate could be a substitute if a
stabilizer was determined necessary. Another possible explanation for not obtaining a
positive Western Blot was that the Pichia hyperglycosylated the protein as yeasts tend
to do that blocked the antigen recognition site. The activity of both forms of the
protease was not affected by the size of dextran sulfate or hyperglycosylation of the
protein. A stabilizer was not used for chymase expression and a successful Western
Blot was achieved.
The media was introduced onto different gravity fed resins including hydrophobic,
anionic, and Traysolol® in an effort to identify a simple but effective method of
purification. The experimentation with each of these resins provided for minimal, if any,
recovery of the enzyme (Data not shown). The lack of recovery could have been due to
hyperglycosylation or, more probably, to the highly charged positive residues attaching
themselves to columns or glass containers. Further research should be undertaken to
identify uncharged purification materials to determine if resins could be employed.
Although the percentage of CatG retained upon purification was not calculated due to
low yields, further research in this area could yield results comparable with chymase’s
2.2 mg/ L. It was considered that improvement in the simple purification steps
employed, such as changing any vessels, flasks, filters, etc to an uncharged or
positively charged design could potentially increase the yields of CatG because the
levels of activity of this enzyme dissipated after contact on these surfaces.
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